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ABSTRACT 
Introduction: 
               Non-fermenting gram negative bacilli (NFGNB) are a group of aerobic, 
nonspore forming bacilli. They are ubiquitous in nature, inhabiting soil, water and also 
present in the hospital environment. NFGNB accounts for nearly 12-16% of all bacterial 
isolates in a clinical microbiology laboratory
.
 The important members are Pseudomonas 
aeruginosa, Acinetobacter baumannii. They cause various infections such as septicemia, 
meningitis, pneumonia, UTI, and surgical site infections. Risk factors include 
immunosuppression, trauma, foreign body, infused body fluids, indwelling catheters, 
prolonged hospital stay and using broad spectrum antibiotics 
Materials and methods: 
         A hospital based cross-sectional descriptive study was undertaken between August 
2014 to May 2015 to  isolate NGFNB from various clinical samples received for culture 
and sensitivity in department of microbiology and environmental samples from ICUs and 
burns unit in tertiary care hospital, Trichy. The NFGNBs were identified using standard 
methods and antimicrobial susceptibility test was performed to determine the sensitivity 
pattern of the isolates. The isolates were screened for imipenem resistance and various 
phenotypic methods like combined disk method, EDS disk synergy test, MBL E- test 
were performed for identification of MBL genes. Genotypic detection of blaVIM and 
blaIMP genes was performed using multiplex PCR.  
 
 
Results: 
            NFGNB was isolated most commonly from pus sample(52.3%). The commonest 
NFGNB to be isolated was P.aeruginosa(58%) followed by A.baumannii(20%). 
P.aeruginosa showed highest sensitivity to imipenem(86%) and A.baumannii showed 
highest sensitivity to Aztronam(80%).14% of P.aeruginosa  were resistant to imipenem, 
and 57% of A.baumannii were resistant to imipenem. In phenotypic tests for MBL 
detection, 6, 8 and 10 isolates showed positivitiy for MBL gene by Combined disc test, 
EDS test, MBL E test respectively. Genotypic study showed that blaIMP was present in 7 
isolates blaVIM gene 3, and in one isolate both the genes were present. In hospital 
environment P.aeruginosa was isolated in 5 sites and A,baumannii in 2 sites. All the 
isolates were sensitive strains. 
CONCLUSION: 
           It is evident from the study that NFGNB are becoming resistant to carbapenems. 
To prevent the spread of the resistant bacteria, it is critically important to have strict 
antibiotic policies.  
Key words: NFGNB, Carbapenem resistance, MBL, blaIMP, blaVIM gene. 
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1.0.INTRODUCTION: 
              Non-fermenting gram negative bacilli (NFGNB) are a group of aerobic, 
nonspore forming bacilli. They either do not use carbohydrates as a source of energy or 
degrade them through metabolic pathways other than fermentation
1.
 They are ubiquitous 
in nature. They are found as saprophytes in nature, inhabiting soil, water and some are 
also found as commensals in human gut
2
. 
              In the hospital environment, they have been isolated from instruments such as 
ventilator machine, mattresses, and other equipments as well as from the skin of 
healthcare workers
3
. They can cause device associated infections, and are often resistant 
to disinfectants and they also have the potential to spread from patient-to-patient via 
fomites or the hands of medical personnel
4
.       
          NFGNB accounts for nearly 12-16% of all bacterial isolates in a clinical 
microbiology laboratory
4.
 The important members of the group in non-fermenters include 
Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and 
Burkholderia cepacia 
5
. They cause various infections such as septicemia, meningitis, 
pneumonia, urinary tract infections, and surgical site infections (SSI) 
2
                 
 Risk factors include immunosuppression, trauma, foreign body, infused body fluids like 
saline irrigations, indwelling catheters,
 
invasive diagnostic as well as therapeutic 
procedures, prolonged hospital stay and using broad spectrum antibiotics
 6 7
. 
            P.aeruginosa , Burkholderhia cepacia and Stenotrophomonas maltophilia are 
important pathogen of patients with cystic fibrosis (CF).They chronically infect the lung 
14 
 
of cystic fibrosis patient and once the infection has occurred, it is almost impossible to 
eradicate the organism. Development of multidrug resistance by non-fermenter isolate 
requires a number of different genetic events. It includes acquisition of mutations and/or 
horizontal transfer of antibiotic resistance genes.  
             P.aeruginosa has greater potential to become resistant to most antibiotics as it is 
clear from the fact that its genome contains the largest resistance island with more than 
50 resistance genes. Mechanism for this antibiotic resistance is due to the production of 
antibiotic-degrading or antibiotic-inactivating enzymes, outer membrane proteins to expel 
the antibiotics and mutations that change the antibiotic targets
 8
. 
                 Production of antibiotic-degrading enzymes such as extended-spectrum beta 
lactamases, AmpC cephalosporinases, carbapenemases like serine oxacillinases, metallo-
beta-lactamases, OXA-type carbapenemases, aminoglycoside-modifying enzymes, 
among others non fermenting gram negative bacilli have been reported 
9 10 11 12
.  
               Carbapenem group of antibiotics are essential in the treatment of nosocomial 
gram negative infections, because of their wide spectrum of activity and stability to 
hydrolysis by most of the β-lactamases, including extended spectrum β-lactamases 
(ESBLs). Carbapenemases are classified mainly into two main molecular families: those 
with serine at their active site, called as serine carbapenemases, and those with at least 
one zinc atom at their active site, known as metallo-carbapenemases which are a 
subgroup of metallo-beta-lactamases (MBLs). Among the MBLs, the VIM and IMP types 
are the most clinically significant carbapenemases coded by blaVIM and blaIMP genes. 
Nosocomial outbreaks of carbapenem-resistant Pseudomonas aeruginosa and 
15 
 
Acinetobacter baumanii because of metallo-β-lactamase (MBL) production have been 
reported from different regions
13 14 15
. 
                  The emergence of these Metalo beta Lactamases in gram negative bacilli is 
becoming a therapeutic challenge, because these enzymes have high hydrolytic activity 
resulting in degradation of higher generation cephalosporins. Therefore the treatment 
options are not available, or very expensive or toxic with poor outcome
16
. The genes 
responsible for the production of MBL may be chromosomally or plasmid mediated. As a 
result they pose a great threat of spread of resistance by gene transfer among the Gram 
negative bacteria. Therefore it is necessary to rapidly detect MBL production to modify 
the treatment and also to start an effective infection control measures to stop their 
dissemination.  
                Hence this study was undertaken to isolate and identify the various non 
fermenters from patients admitted in our tertiary care hospital and from environmental 
source as they are ubiquitously distributed and to study their antimicrobial susceptibility 
pattern and carry out phenotypic tests to identify carbapenemase producers and to 
identify the various health care associated infections they cause. 
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AIM AND OBJECTIVES 
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2.0 AIM OF THE STUDY 
 
 To estimate the prevalence of  nonfermenters in various clinical samples in a 
tertiary care hospital   
 To assess frequency of isolation of non fermenters in hospital environments such 
as ICUs burns unit, etc.  
  
 To study the antimicrobial susceptibility pattern of the isolates & to estimate the 
antibiotic resistance rate. 
 
 To correlate the clinical sample & environmental isolates  with the clinical 
infections 
 To detect MBL by phenotypic and genotypic methods among imipenem resistant 
isolates. 
  To create awareness on prevention of hospital acquired infection related to 
nonfermenters among hospital staff and judicious use of antibiotics. 
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                    3.0. REVIEW OF LITERATURE 
                     
               The NFGNBs are a group of Gram negative bacilli or coccobacilli which do not 
make use of carbohydrate as a source of energy by fermentation and hence termed as 
„Non-fermenters‟. However, they may utilize carbohydrate by oxidative method .The 
NFGNBs have been defined as all aerobic Gram negative bacilli that shows abundant 
growth within 24 hrs on the surface of TSI medium but neither grows in nor acidifies the 
butt of the media
1
.
 
 3.1. HISTORICAL PERSPECTIVE: 
              Before the advent of modern medical microbiology there was evidence that 
Pseudomonas aeruginosa was a cause of serious wound and surgical infections as 
eloberated by Doggett. In 1850, Sedillot noted that there were blue-green discharges on 
surgical dressings that were associated with infection
17
.  
    The pigment was extracted by Fordos in 1860 and a crystalline substance pyocyanin 
was isolated
18
.  
In 1862, Luke noted rod shaped microorganisms were associated with within the blue 
green pus. It was Gessard who isolated the organisms and designated them as Bacillus 
pyocyaneus in 1882
17
.  
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   Osler in 1925 thought that the organism to be more of a secondary or opportunistic 
invader of damaged tissue as opposed to primary cause of infection in healthy tissue.  In 
1960s, it has emerged as a major human pathogen because of its ability to cause 
infections in immunocompromised hosts. 
              The genus Acinetobacter has suffered a long history of taxonomic change. The 
first member of the group described was a soil organism by enrichment in a calcium-
acetate-containing minimal medium isolated by Beijerinck in 1911, and named by him as 
Micrococcus calcoaceticus. The genus Acinetobacter was proposed by Brisou and Prevot 
in 1954 
17 18
.     
                In 1959, American bacteriologist Elizabeth O.King isolated the organism from 
a case of peadiatric meningitis and named it as Flavobacterium meaning „yellow bacillus‟ 
in Latin and meningosepticum likewise means associated with meningitis and septicemia. 
In 1954, it was reclassified in the genus Chryseobacterium, and was named 
Chryseobacterium meningosepticum , chyseo meaning „golden‟19. In 2005, it was placed 
in the genus Elizabethkingia named after the original discoverer of F.meingospticum  
meaning  “unable to move” was adopted in 1969. 
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3.2. HABITAT: 
    Non fermenters have their natural habitat in environment and hence serve as 
potential reservoir for human infections 
1  20 21 22
. 
   1. Water reservoirs prevalent in hospital humidifiers, nebulizers, waterbaths, 
disinfectants, irrigation solutions, distilled water lines, soaps, injectable drugs.  
2.     Implements, such as anesthetic equipment, forceps, thermometers that may be stored 
in disinfectant solutions, and mops, sponges and towels, contact lens solutions.  
3.    Most intertriginous parts of the skin and mucous membrane, toe webs, groin, axilla 
and antecubital fossa, throat, nasal mucosa, gastro intestinal tract. 
           They can be colonizers or cause wide spectrum of diseases. NFGNBs are known 
to colonize first and then they subsequently invade the otherwise normally sterile site 
through trauma. It has been noted that disruption of natural barriers as an important route 
of entry of infections. 
3.3. METABOLISM: 
    3.3.1. BACTERIAL PHYSIOLOGY OF NON-FERMENTERS: 
             NFGNB refers to all aerobic gram negative rods that show abundant growth on 
the surface of Triple sugar iron agar or Kligler iron agar (KIA) but do not grow or acidify 
the butt of these media
1 23
. Most of the routinely isolated, medically important bacteria 
utilize carbohydrates by one or several different pathways. However, some bacteria 
belonging to NFGNB like Moraxella species do not use carbohydrates as a source of 
22 
 
energy. They derive energy from others sources such as amino acids, alcohols and 
organic acids 
1
 . 
        The differentiation between NFGNB and other fastidious organisms which do not 
ferment glucose is based on convention rather than well defined genotypic or phenotypic 
characters
1
. In order to gain a clear understanding of NFGNB, it is important to 
understand the different metabolic pathways utilized by these organisms. 
 
  3.3.2. Fermentative and oxidative metabolism 
1 24 17 
     
        The bacterial degradation of carbohydrates proceeds by several metabolic 
pathways in which hydrogen ions are successively transferred to compounds of higher 
redox potential, with the ultimate release of energy in the form of adenosine triphosphate 
(ATP). All six-, five-, and four- carbon carbohydrates are initially degraded to pyruvic 
acid, an initial intermediate. Glucose is the main carbohydrate source of the carbon for 
bacteria and degradation proceeds by three major pathways: 
 1. The Embden- Meyerhof- Parnas pathway 
2. The Entner- Doudoroff pathway 
3. The Warburg-Dickins/ The Hexose monophosphate pathway 
       Glucose is converted to pyruvic by a series of reactions in each of these three 
pathways. Bacteria use one or more of these pathways of glucose metabolism depending 
on the availability of oxygen and the presence of enzymes within the organism.         
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The Embden-Meyerhof- Parnas (EMP) pathway: 
     It is also called the glycolytic or anaerobic pathway because glucose is degraded 
without the use of oxygen. This has been called the fermentative pathway as so organic 
compounds serve as the final electron acceptors. End products formed from this pathway 
are the mixed acids, which account for the drop in the pH in the fermentation tests. 
 The Entner – Doudoroff (ED) Pathway: 
            This is called the aerobic pathway because oxygen is required for glycolysis. This 
has been classically called the oxidative pathway, because pyruvic acid transfers the 
electrons into Kreb‟s cycle, where they are linked to elemental oxygen to form water. 
Therefore, through this pathway, the carbohydrates are oxidatively metabolized, where 
oxygen is required as the terminal electron acceptor. 
             The acids formed in this pathway are extremely weak and hence cannot be 
detected by the routinely used tests. Many of NFGNB use this pathway of carbohydrate 
metabolism. 
 The Warburg–Dickens/ Hexose Monophosphate Pathway: 
        This pathway is a hybrid between the EMP and ED pathways. It is used mainly by 
facultatively anaerobic organisms. Mixed acids are formed as end products in this 
pathway also. Hence the organisms using this pathway give fermentative reaction in 
routinely used biochemical tests. 
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3.4. CURRENT CLASSIFICATION: 
       The NFGNB do not fit into a single family of well- characterized genera1. The 
correct taxonomic placement of many of the NFGNB is still unsolved. The major genera 
of gram negative bacilli have been classified into 15 families including Alcaligenaceae, 
Alteromonadaceae, Brucellaceae, Burkholderiaceae, Flavobacteriaceae, 
Methylobacteriaceae, Morxellaceae, Oceanospirillaceae, Pseudomonadaceae, 
Rhizobiaceae, Sphingobacteriaceae, Sphingomonadaceae and Xanthomonaceae
1
.  
        The medically important non-fermenters can also be classified depending on the 
presence or absence of motility and the type of flagella they possess as follows 
1 
. 
      Table 1: Classification of NFGNB based on motility and type of flagella        
 
     MOTILE  WITH POLAR FLAGELLA 
 
           Family Pseudomonadaceae 
            (rRNA group I) 
            Genus Pseudomonas 
            Family Burkholderiaceae 
            (rRNA group II) 
            Genus Burkholderia 
            Genus Cupriavidus 
            Genus Lautropia 
            Genus Pandorea 
            Genus Ralstonia 
            Family Comamonadaceae 
            (rRNA group III) 
25 
 
            Genus Comamonas 
            Genus Acidovorax 
            Genus Delftia 
            Family Caulobacteriaceae 
            (rRNA group IV) 
            Genus Brevundimonas         
            Family Xanthomonadaceae 
            (rRNA Group V) 
            Genus Stenotrophomonas 
            Family Sphingomonadaceae 
            Genus Sphingomonas 
            Family Oceanospirillaceae 
            Genus Balneatrix  
            Genus Massilia 
          Family Alteromonadaceae 
 
              Genus Shewanella 
 
              Genus Alishewanella  
            
        Family Oxalobacteriaceae 
 
              Genus Herbaspirillum 
  
                 Genus Massilia 
 
   Organisms with uncertain taxonomic 
positions 
26 
 
 
     CDC Groups Ic, O-1, O-2, O-3, Vb- 3 
       MOTILE WITH PERITRICHOUS 
                     FLAGELLA  
                  Family Alcaligenaceae 
 
                   Genus Achromobacter 
                   Genus Alcaligenes 
                   Genus Bordetella 
                   Genus Kerstersia 
                   Genus Oligella 
             Family Rhizobaceae 
                 Genus Rhizobium 
             Family Brucellaceae 
                  Genus Ochrobactrum 
              Family Halomonadaceae 
                   Genus Halomonas 
                       NON MOTILE 
OXIDASE POSITIVE 
Family Flavobacteriaceae 
                 Genus Flavobacterium 
                 Genus Bergeyella 
 Genus Chryseobacterium 
                 Genus Empedobacter 
                 Genus Myroides 
                  Genus Weeksella 
27 
 
              Family Sphingobacteriaceae 
                Genus Sphingobacterium 
                Genus Pedobacter 
               Family Moraxellaceae 
                  Genus Moraxella 
                  Genus Psychrobacter 
                Family Neisseriaceae 
                   Genus Neisseria 
                Family Alcaligenaceae 
                   Genus Oligella 
                   NON MOTILE, 
             OXIDASE NEGATIVE 
                  Family Moraxellaceae 
                   Genus Acinetobacter 
       Organisms whose taxonomic position is        
uncertain 
                  CDC group NO-1 
                  CDC group EO-5 
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3.5. CHARACTERISTICS OF EACH FAMIY: 
3.5.1. MOTILE WITH POLAR FLAGELLA: 
 Pseudomonads: 
        This consists of the genus Pseudomonas and some closely related genera many of 
which were formerly placd under in the genus Pseudomonas, make up a group often 
referrd to as Pseudomonads.The common characteristics of pseudomonads are – they are 
motile by means of a polar flagella. They are slightly curved or straight Gram negative 
rods. Most of them are oxidase positive
17 18 25 
.  
 
  Family Pseudomonadaceae: 
      This consists of the genus Pseudomonas. Currently there are 160 species of 
Pseudomonas, of which 12 are medically important. Two schemes have been developed 
for classifying the organisms under this family. Gilardi separated the pseudomonads into 
7 groups on the basis of phenotypic characters: fluorescent, stutzeri, alcaligenes, 
pseudomallei, acidovorans, facilis-delafieldii and dimunita
26
.  
      On the other hand, Palleroni separated the family into 5 ribosomal RNA groups using 
rRNA-DNA hybridization aid in identification, the species are divided into the following 
important groups
27
.  
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Phenotypic classification of the pseudomonads (polar flagellated NFGNBs): 
rRNA GROUP 1 
    Fluorescent group                - Pseudomonas aeruginosa 
                                                 - Pseudomonas fluorescens 
            -  Pseudomonas putida 
    Stutzeri group       - Pseudomonas stutzeri 
          Pseudomonas mendocina 
          CDC group Vb-3 
   Alkaligenes group              -  Pseudomonas alcaligenes 
                          Pseudomonas pseudoalcaligenes 
     
rRNA GROUP 2 
     Psuedomallei group        - Burkholderia mallei 
                        - Burkholderia pseudomalei 
    - Burkholderia cepacia complex 
    - Burkholderia gladioli 
    - Pandorea species 
                         -  Ralstonia species 
             -  Cupriavidus species 
rRNA GROUP 3 
     Weak oxidizer group – Comamonas acidovarans  
                                           Comamonas terrigena 
              Acidovorax delafieldii 
             Acidovorax facilis 
            Acidovorax temperans 
            CDC WO-1 
rRNA GROUP IV 
      Dimunita group       - Brevindimonas dimunita 
30 
 
        - Brevindimonas vesicularis 
    
rRNA GROUP V 
-Strenotrophomonas maltophilia 
Yellow Pigmented group 
-Pseudomonas luteola 
             - Pseudomonasoryzihabitans 
             -Sphingomonas paucimobilis 
 
H2S positive group  
          -Shewanella putrefaciens 
         - Shewanella algae 
Halophilic group  
-Alishewanella fetalis 
-Haolmonas venusta 
-CDC halophilic non fermener group I 
 
 FLUORESCENT GROUP: 
           The three main species in this group are Pseudomonas aeruginosa, Pseudomonas 
fluorescens and Pseudomonas putida. They are characterized by the production of water 
soluble pyoverdin pigment which fluoresces white to blue-green under ultraviolet light at 
the wavelength of 400nm. This pigment is enhanced in media containing high phosphate 
concentration
28 29 30
.  
     Of these, only Pseudomonas aeruginosa produces the blue-green pigment pyocyanin. 
These pigments are easily identified in nutrient agars and sensitivity test agars
31
. 
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Table 2: Key characteristics of the Fluorescent group 
  TEST P.AERUGINOSA P.FLUORESCENS P.PUTIDA 
Pyocyanin           +           -          - 
Pyoverdin           +          +          + 
NO3 reduction           V          V          - 
Growth at 42
0
C           +           +            + 
 
 P.aeruginosa: 
       It is the most common Pseudomonad frequently encountered from clinical 
specimens. It is prevalent among patients with burn wounds, cystic fibrosis, organ 
transplants
33
. Infection occurs at the place where moisture tends to build up like 
tracheostomies, indwelling catheters and burn wounds. It causes urinary tract infections, 
nosocomial pneumonia, and also devastating keratitis and endophthalmitis
1 2
.  
 
Table 3: Virulence factors of P.aeruginosa:
 1 33 34
: 
Virulence factors Human effects 
Lipopolysaccharide 
endotoxin 
Cascade of inflammatory events , septic shock 
Mucopolysaccharide 
capsule 
Adhesion to epithelial cells, barrier to antibiotics, 
increased viscosity to bronchial secretions 
Pili Act as adhesions 
32 
 
Proteases (alkaline & neural 
metalloproteinase) 
Damage tissues (active on elastin, collagen, fibrin) 
Digestion of protecting proteins serving as host defenses 
Neuraminidase Enhances pilin mediated adherence 
Phenazine pigment Ciliary distruption 
2 hemolysins : 
Phospholipase C glycolipid-
rhamnolipid (heat stable)  
 Distruption of Phospholiids of cell membranes, 
hydrolysis of lung surfactant and ciliostatic action 
Siderophores Help growth in iron limited conditions. Generation of 
toxic oxygen free radicals 
Exotoxin A Causes tissue damage, inhibits phagocytes, inhibits 
protein synthesis 
Exoenzyme S Binding specificity for glycolipids 
Cytotoxin : leucocidin  Cytopathic effects on leucocytes and alteration of 
phospholipids on cell membranes 
Antibiotic inactivating 
enzymes 
β lactamases, Aminoglcoside inactivating enzymes 
 
Host factors in pathogenesis: 
           Because the major manifestations of P.aeruginosa infection are nosocomial 
infection, chronic lung infection in CF, and contact lens associated keratitis, it is clear 
that the primary determinant of virulence factor is the health status of the host. Healthy 
humans are generally highly resistant to P.aeruginosa infection and 
immunocompromised status of the host is an important risk factor. Although many 
factors contribute to the host susceptibility to P.aeruginosa infection, one important 
33 
 
factor for community-acquired and nosocomial P.aeruginosa infection appear to be 
neutropenia
18
.  
        Innate immune resistance to P.aeruginosa infection starts with the anatomic barrier 
function of the skin and mucosa surfaces, and any disruption to the integrity of these 
barriers establishes a situation in which P.aeruginosa can become invasive. Typically 
problems are associated with burn wounds and use of intravenous or urinary catheters, 
and particularly use of endotracheal tubes
18
.  
    In burned and wounded skin, P.aeruginosa grows to sufficient levels to elaborate a 
multitude of toxins. One of the important factors implicates in pathogenesis is elastase. 
      Soluble host factors present on mucosal surfaces that have been implicates in high 
level resistance to P.aeruginosa include complement proteins, lung surfactans, and 
similar members of collectin family
18
.       
IDENTIFICATION: 
MORPHOLOGY AND STAINING: 
     It is a thin, motile Gram negative non sporing bacillus usually with a single polar 
flagellum 
1 31
.  
CULTURAL CHARACTERISTICS: 
     It grows readily on ordinary media. In Nutrient agar it produces, six distinct colony 
types
31
.  
Type 1 – large, low convex, rough in appearance, and often oval with long axis in the line 
of the inoculum streak. (Most common type) 
Type 2 – small, smooth, doomed 
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Type 3 – small and rough 
Type 4 – small rugose 
Type 5 – mucoid alginate producing type (seen in Cystic fibrosis patient) 
Type 6 – dwarf colonies 
         On blood agar, it has a characteristic appearance. It appears as large gray colonies 
with spreading periphery .colonies often have a alligator skin appearance and exhibit a 
metallic sheen
1
. 
    Cultures produces characteristic grape like smell of aminoacetophenone. It produces 4 
distinct pigments, pyocyanin, fluorescin, pyorubin, pyomelanin. King, Ward, and Raney 
developed Pseudomonas agar P (King A medium) for enhancing the production of 
pyocyanin and pyorubin pigment, and Pseudomonas agar F (King B medium) for 
enhancing fluorescein pigment production
31 28
.  
SELECTIVE MEDIA:  
         Cetrimide agar with nalidixic acid, Irgasan containing media are commercially 
available for selective isolation of P.aeruginosa especially from environmental sites
31
.  
BIOCHEMICAL REACTIONS: 
        It is catalase, oxidase and citrate positive and indole negative, do not produce H2S, 
MR,VP negative, utilizes glucose only oxidatively, forming only acid. Nitrates are 
reduced to nitrates and further to gaseous nitrogen. Arginine hydrolase test is positive
1 31
.  
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TYPING METHODS: 
        The classification and typing of P.aeruginosa is essential for epidemiological 
purposes as it has become a very important nosocomial pathogen.    
         Biotyping, Resistance phenotyping, serotyping, pyocin typing, bacteriophage typing 
were used but they are now replaced by molecular typing methods like Plasmidotyping, 
DNA fingerprinting, Ribotyping and Pulsotyping (most reliable technique)
 35
.                         
TREATMENT: 
             Management of P.aeruginosa infections may not be easy as only a narrow 
spectrum of drugs is effective against this organism. The drugs that are commonly used 
to treat the infections are carboxypenicillins (Carbenicillin, Ticaricillin) the 
ureidopenicillins (Piperacillin), the anitpseudomonal cephalosporins (Ceftazidime), 
monobactums (Aztreonam), carbapenems (Imipenem and Meropenem) and 
aminoglycosides (Gentamicin, Tobramycin, Amikacin). P.aeruginosa has the capability 
of carrying multiresistance plasmids and this feature has led to the emergence of some 
P.aeruginosa strains that are resistant to all antibiotics
36 37
. Colistin is increasingly 
becoming the drug of choice for such pan-resistant organisms. 
 P.fluorescens and P.putida :  
                 These species are easily distinguished from P.aeruginosa by their inability to 
form pyocyanin or grow at 42
0
C. Both species are psychrophilic and survive at 
refrigerator temperatures. Therefore they may multiply in stored blood and related 
36 
 
products and give rise to fatal reactions when injected intravenously 
18
. They are isolated 
from hospital floors, sinks etc. 
           It causes infections like pneumonia, catheter-related blood stream infections, acute 
cholecystitis and cholangitis, tonsillitis, thrombophlebitis, septic arthritis and skin and 
soft tissue infections 
38
.  
 Stutzeri group. 
                     This group includes P. stutzeri, P. mendocina and the unnamed CDC group 
Vb-3. These organisms are soil denitrifiers and can grow with ammonia as their sole 
source of nitrogen 
1 39
. 
                  P. stutzeri has been recovered from variety of sources like soil, water, manure, 
sewage, straw, baby formula, hospital equipments, eye cosmetics and various clinical 
samples
42
. It is a rare human pathogen and has been associated with infections like otitis 
media, pneumonia, conjunctivitis, endodcarditis and meningitis in HIV- positive 
individuals
40
. 
      Colonies appear dry and wrinkled on primary isolation, which pit or adhere to the 
agar plate. They may be buff or brown in color
39
. 
           P.mendocina and CDC group Vb- 3 are very rarely isolated from clinical samples. 
P.mendocina has been isolated from a case of endocarditis following mitral valve 
replacement 
41 42
.  It produces smooth, buttery colonies. CDC group Vb-3 has been 
isolated from a case of multiple myeloma patient 
43
. 
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ALCALIGENES GROUP: 
             The organisms in this group include P.alcaligens, P.pseudoalcaligenes, and 
Pseudomonas species CDC group 1. They are asaccharoytic and weakly saccharolytic in 
OF glucose medium. They rarely case human infections like eye infections, empyema 
and one case of fatal endocarditis have been reported
44
.  
 YELLOW PIGMENTED GROUP: 
              P.lutola and P.oryzihabitans are included in this group. P.luteola is motile by 
multitrichous polar flagella, oxidase negative. In Mac Conkey and blood agar, it produces 
yellow coloured colonies that are wrinkled and are adherent to the agar
1
. They rarely 
cause human infections and has been isolated from cases of meningitis, septicemia, 
peritonitis, osteomyelitis
45 46
.  
        P.oryzyhabitans is also motile, oxidase negative. Like P.luteola they also form 
rough, wrinkled colonies. They can be differentiated from P.luteola by being negative for 
esculin hydrolysis and by having single polar flagellum. They appear to an emerging 
pathogen in peritonitis related to continuous ambulatory peritoneal dialysis
47
.  
Family Burkholderiaceae: 
rRNA GROUP II  
      All species in this group belong to the genus Burkhloderia. They are differentiated 
from  Pseudomonads group by exhibiting resistance to polymyxin B and colistin.  
     The most important species of the genus Burkholderia is Burkholderia cepacia, 
Burkholderia pseudomallei and Burkholderia mallei.  
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 Burkholderia cepacia: 
               It has emerged as opportunistic infections in patients with chronic 
granulomatous disease and cystic fibrosis
48
. It has been isolated from wet sources and wet 
surfaces, including detergent solutions, intravenous fluids, nebulizer solutions, mouth 
washes. Clinical infections include pneumonia, pneumonitis in patients receiving 
contaminated anaesthetics, urinary infection in patients receiving contaminated irrigation 
fluids, endocarditis due to contaminated heart valves. 
              Patients acquire infection from environment or via patient to patient. They cause 
skin and soft tissue infection in individuals with burns and surgical wounds and 
genitourinary tract infection following instrumentation
17
.    
               Selective media with bacteriostatic dyes, antibiotics, or low pH have been 
described for selective isolation of B.cepacia. These include Pseudomonas cepacia 
medium (PCM), containing crystal violet, polymyxin B and ticarcillin 
49
,OFLB medium 
containing polymyxin B, bacitracin and lactose
50 
and Burkholderia cepacia selective agar 
(BCSA) containing lactose, sucrose, polymyxin B, gentamicin, and vancomycin. Studies 
show that recovery of this organism in patients with cystic fibrosis is enhanced with their 
use
51
.  
 Burkholderia mallei: 
                It is oxidase positive, aerobic and non motile. It causes glanders which is a 
highly communicable disease of horses and mules and recognized as an occupational risk 
for horse handlers, veterinarians and lab workers.  
39 
 
                 Human glanders can be acute or chronic, with mode of infection, inoculating 
dose and host factors determining the clinical course. Infection occurs either by 
inhalation or direct inhalation or direct inoculation
52
. They are resistant to beta lactam 
antibiotics including first and second generation cephalosporins. The antibiotics used 
include aminoglycosides, macrolides, carbapenems and doxycycline
52
.  
 Burkholderia pseudomallei: 
         Burkholderia pseudomallei cause meliodisis, a glanders like diseases in animals and 
humans. The bacterium is found in contaminated soil and water. Infections are acquired 
by contact with the organisms either by inhalation of dust or direct contact through breaks 
in the skin.  
          It is oxidase positive, motile with polar flagella, arginine dihydrolase and gelatin 
positive and produce acid in OF lactose. On staining it shows bipolar safety pin pattern 
52
 
. This organism grows well on routine laboratory media and often produces wrinkled 
colonies with distinctive earthy odour 
53
.  
    Selective agars like Ashdown‟s selective agar (ASA) are used for isolation of the 
organism from non sterile sites
54
.  
             An important feature of this disease is it produces latent infection that can 
reactivate years after primary exposure. Three forms of melidiosis has been described; 
Acute disease presenting as septicemia with metastatic lesion, subacute disease 
presenting as pneumonia, and chronic disease presenting as chronic cellulitis.  
          Treatment should be started early in the course of disease
1
.  
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 Burkholderia gladioli: 
          Burkholderia gladioli is one of the few pseudomonads which is oxidase negative. 
Rarely does it cause human infctions like chronic granulamatous infections, soft tissue 
infections, keratits and endophthalmitis in patients with diabetes mellitus.  
 rRNA GROUP III: 
      It consists of family Comamonadaceae 
   Acidovarans group: 
          This group consists of Comamonas acidovarans, Comamonas testosterone and 
Comamonas terrigena. All are motile with tuft polar flagella. Acid is not produced in OF 
glucose medium and thus these organisms are grouped among the alkaline 
pseudomonads
1
. 
           Comamonas acidovarans was placed in new genus Delftia.  D.acidovarans is the 
most common of this group to be isolated from clinical specimens. It has the unique 
feature of producing an orange indole reaction due to the production of anthranilic acid 
from tryptone
1
.  
Facilis-delafieldii group: 
   This group includes Acidovorax facilis, Acidovorax delafieldii and Acidovorax 
temporans. acidovorax delafieldii and acidovorax temporans have been isolated from 
clinical specimens. 
 rRNA GROUP IV: 
      All species in this group have transferred to new genus Brevundimonas. This group 
consists of Brevundimonas diminuta and Brevundimonas vesicularis. Brevundimonas 
41 
 
vesicularis is slow growing and produces dark yellow pigment. It has been isolated from 
dialysis fluid, oral abscess, scalp wound and in blood
1
.  
  rRNA GROUP V:           
GENUS STENOTROPHOMONAS: 
               It is the third most frequently encountered non fermenter
1
.  (Koneman 2006) 
They are gram negative rods, motile and susceptible to Polymyxin B. Stenotrophomonas 
maltophilia, is an emerging nosocomial pathogen. Most commonly present in 
environment (rivers, wells, sewage, and bottled water) and food stuffs like fish, milk, 
eggs. They are often recovered from respiratory tract. They have known to cause 
pneumonia, bacteremia, endocarditis, cholangitis, UTI, meningitis, wound infections, 
intra abdominal abscess, conjunctivitis, keratitis
24
.  
Important identification features:  
-oxidase negative  
-Oxidizes glucose and maltose  
-DNase and lysine decarboxylase  
 
On Blood agar, it appears rough, lavender gray with ammonium odour.  
 
            S. maltophiila is inherently resistant to commonly used antipseudomonal drugs. 
This favours colonization of this organism and increases the risk of infection. It is 
inherently susceptible to trimethoprim-sulfamethoxazole which has become the drug of 
choice in treating infections due to S.maltophilia 
1
. 
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 Genus Sphingomonas: 
                  S.paucimobilis is the most common species recovered from clinical infections. 
It is a gram negative motile rod which is oxidase positive. Isolates are strongly esculin 
hydrolysis and produces zone of inhibition around vancomycin disk (30µg) placed on 
BAP. They have been recovered from variety of clinical infections like septicemia, 
meningitis, wound infections and also from hospital environment
55
.  
    Most of the strains are susceptible to tetracycline, chloramphenicol, trimethoprim-
sulfamethoxazole and aminoglycosides. 
GENUS SHEWANELLA – HYDROGEN SULFIDE PRODUCING GROUP: 
                This genus consists of around 22 species. Most important species are 
S.putrefaciens, and S.algae. S.algae is the one which is predominantly isolated from 
human infections and S.putrefaciens represents majority of non human isolates. S.algae 
requires NaCl for its growth. 
    They are easily distinguished from other groups because these are the only non 
fermenters which produce hydrogen sulfide in KIA and TSI
1
. (Koneman 2006) They 
have been isolated from skin ulcers, eye infections, ear infections, arthiritis, endocarditis, 
bacteremia
56
.They are generally susceptible to most antimicrobial agents except 
penicillin, cephalothin.  
GENUS ALISHEWANELLA – HALOPHILIC GROUP: 
          Alishewanella fecalis is a halophilic organism which requires Nacl for its growth. It 
does not produce hydrogen sulfide in TSI agar.  
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3.5.2 MOTILE WITH PERITRICHOUS FLAGELLA: 
   GENUS ALGALIGENS: 
       A.fecalis is the most frequently isolated species. It produces strong alkaline reaction 
in al carbohydrate media. It produces characteristic fruity odor (odor of green 
apples)
1
.(Koneman 2006) It exists in soil and water and have been isolated from clinical 
infections like acute otitis media, urinary tract infections and bacteremia
57 58
. 
GENUS ACHROMOBACTER: 
       A.xyloxidans oxidizes OF glucose and xylose, hence the name. It has been isolated 
from blood, CSF, bronchial washings, urine, pus wound. 
 
 3.5.3 NON MOTILE, OXIDASE POSITIVE: 
FAMILY FLAVOBACTERIACEAE: 
    Chryseobacterium species are long, thin and slightly curved GNB. Chryseobacterium 
meningosepticum colonies usually form dark, yellow pigments in culture, and fail to grow 
on MacConkey agar. They are non motile, produce positive catalase and oxidase 
reactions
1
.  
                   Ubiquitous in nature, they are inhabitants in soil and water. Frequent 
colonization of patients via contaminated medical devices has also been reported.  
         Chryseobacterium meningosepticum is a cause of neonatal meningitis, especially in 
premature infants during the first two weeks of life. Clusters of neonatal meningitis have 
been linked to many sources including contaminated saline solutions for flushing eyes, 
ventilators and sink drains. In adults it causes endocarditis, pneumonia, and septicemia. 
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           Environmental studies show that they can survive in chlorine treated municipal 
waters, and colonizes sink and it is a potential reservoir for infection in hospital 
environment
59
.  
        It has got a unusual antibiotic profile. It is intrinsically resistant to most of the 
antibiotics which is used to treat gram negative infections like aminoglycosides, β-lactam 
agents, Chloramphenicol, carbapenems but susceptible to agents used to treat gram 
positive bacteria like Rifampicin, Ciprofloxacin, Vancomycin, trimethoprim–
sulfamethoxazole. So the choice of treatment is difficult. The disc diffusion methods are 
not reliable and broth microdilution is the preferred method for detection of antibiotic 
susceotibility. Although vancomycin has been used to treat infection some studies shows 
resistance to vancomycin and minocycline, trimethoprim-sulphamethoxazole and 
rifampicin may be used as alternative drugs
60
.  
  GENUS SPHINGOBACTERIUM: 
      The genus Sphingobacterium is yellow pigmented, oxidase positive and non motile. 
S.multivorum and S.spiritivorum are the two important species mostly isolated from 
human infections.  
  GENUS MORAXELLA: 
      These are tiny non motile gram negative diplococci which are oxidase and caalse 
positive. The medically important species are M.lacunata, M.nonliquefaciens, 
M.catarrhalis. 
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       Moraxella are normal flora on mucosal surfaces and are considered to have low 
pathogenic potential. They occur most frequently in respiratory tract, less commonly 
genital tract infection and rarely cause systemic infections.  
    Most of the strains are susceptible to penicillin, cephalosporins, tetracycline, 
quinolones and aminoglycosides
1
.  
 
3.5.4 NON MOTILE, OXIDASE NEGATIVE: 
GENUS ACINETOBACTER: 
           It is the second most frequent non fermenter isolated from clinical laboratories.  
They are strictly aerobic, gram negative coccobacilli that are oxidase negative, non-
motile, nitrate reduction test negative
1
.Originally, the genus was placed under the family 
Neisseriaceae, but now it has been moved to family Moraxellaceae. 
              The important species belonging to this genus are Acinetobacter baumannii, 
Acinetobacter lwoffii, Acinetobacter haemolyticus, Acinetobacter calcoaceticus and 
Acinetobacter junii.
61 62
. 
Morphology and staining: 
      In gram stain, they appear as cocci or coccobacilli.  
Cultural characteristics: 
    On Mac conkey agar, colonies show slightly pinkish tint. On blood agar, they are not 
pigmented.  
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Biochemical reactions: 
      They are cytochrome oxidase negative, citrate positive, non motile, oxidizes glucose 
rapidly with the production of acid, oxidizes 10% lactose rapidly with the production of 
acid, and negative for nitrate reduction
31
.  
Table 4:  Identification of Acinetobacter species: 
TEST A.baumannii A.lwoffii 
OF Glucose Saccharolytic Asaccharolytic 
Arginine dihydrolase Positive Negative 
Growth at 42
0
C Positive Negative 
10% Lactose Positive Negative 
Chloramphenicol sensitivity Resistant Sensitive 
 
              Acinetobacter tend to be resistant to wide range of antibiotics, although one 
species, A.lwoffii, tends to be more sensitive to others. They are almost universally 
resistant to ampicillin, cephalothin, and most srains and are resistant to chloramphenicol.  
In recent years there has been increased resistance towards aminoglycoside resistance and 
carbapenem resistant strains in nosocomial outbreaks
63
. 
Treatment: 
              For serious infections combined treatment with aminoglycoside and ticarcillin or 
pipericillin is synergistic and effective. The only antimicrobial agent which is proved 
active against MDR Acinetobacter is colistin 
1
.   
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3.6.  ANTIBIOTIC RESISTANCE MECHANISMS: 
                     Antibiotic resistance is a international problem of foremost importance 
64
. 
Isolations of multi-drug –resistant, extensively drug resistant or even pan drug resistant 
gram negative pathogens are causing major therapeutic problems and at the same time are 
posing infection control issues in many health care centres. This results in increased 
morbidity and mortality of the patients, increased length of hospital stay and higher 
hospital costs 
65
. 
                   P.aeruginosa is a opportunistic nosocomial pathogen. They are responsible 
for variety of infections and show high rates of resistance to antibiotics. This is due o the 
fact that its genome is among the largest in the bacterial world allowing for larger genetic 
capacity and high adaptableness to environmental changes. It has 5567 genes encoded in 
6.26 Mbp of DNA 
8 70
. This largest genome is further enriched with addition of genes 
acquired by transferable genetic elements is a major contributing factor for development 
of resistance against all known antibiotics
70
.   
         Three classes of antimicrobial resistance have been described. 
1. Intrinsic resistance 
2. Acquired resistance 
3. Genetic resistance    
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INHERENT RESISTANCE 
66
: 
    Inherent resistance to antimicrobial agents occurs through variety of mechanisms.  
1) Decreased outer membrane permeability  
2) Efflux systems 
3) Synthesis of antibiotic inactivating enzymes 
Outer membrane permeability: 
                   Outer membrane of GNB is a semipermeable barrier which blocks the uptake 
of antibiotics and soluble molecules to pass through it. Sequential analysis of genes have 
identified 163 predicted outer membrane proteins which have grouped into three families 
of porins. The role of these porins is transport of sugars, aminoacids, divalent cations. 
Certain hydrophilic antibiotics like beta lactam antibiotics, aminoglycosides, 
fluoroquinolones also transverse the outer membrane through porins.  Aminoglycosides 
and colistin ineract with the lipopolysaccharides of the outer membrane so as to pass 
through the membrane. Beta lactam antibiotics and quinolones disseminate through some 
porin channels. 
           The outer membrane of P. aeruginosa is only 8% as permeable as the outer 
membrane of Escherichia coli. 
      Most bacteria have lot of general porins and a relatively few specific porins. But 
P.aeruginosa express mainly specific porins. Loss of certain specific porin channels lead 
to reduced susceptibility of the antibiotics
67
.  
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         The OprD porin of P.aeruginosa is a substrate-specific porin permits the diffusion 
of basic amino acids, and carbapenems into the cell and loss of OprD porin from the 
outer membrane notably reduces the susceptibility of the organism to available 
carbapenems
19
. 
       The Porins of B.cepacia and Acinetobacter sp have small porin channels 
67 68
. (Gotoh 
1994; Sato 1991) The porin size of S.maltophila is same as that of E.coli but in low copy 
numbers
70
. 
  Efflux systems 
37
: 
              P.aeruginosa posses a number of efflux pumps that actively pump the antibiotic 
out of the cell. This mechanism has been implicated in resistance of the organism to 
tetracycline, quinolone and beta lactams. 
    They consists of three proteins:  
1) protein transporter of cytoplasmic membrane  
2) periplasmic connective protein ,  
3) an outer membrane porin.  
     These efflux system expels most of the antibiotics except polymyxins
71
. 
 
 Antibiotic inactivating enzymes: 
           All strains of P.aeruginosa produce a chromosomally mediated AmpC-type beta 
lactamases and few plasmid mediated beta lactamases. Normally the chromosomal 
AmpC enzyme is in a repressed state but it can be strongly induced by first generation 
cephalosporins, cefoxitin and ampicillin. These antibiotics are liable to these enzymes as 
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well as strong inducers. Third generation cephalosporins and ureidopenicillins are also 
liable to the enzyme but do not induce its synthesis. So they are active as long as the 
enzyme is not induced. However stably derepressed mutants that produce AmpC 
copiously arise spontaneously and can be selected in vivo during cephalosporin or 
ureidopenicillin therapy. These mutants are resistant to all beta lactams except to 
imipenem and sometimes carbenicillin.    
            A. baumannii innately produces an AmpC-type cephalosporinase. They are also 
known as Acinetobacter-derived cephalosporinases (ADCs).In A. baumannii inducible 
AmpC expression does not occur unlike other gram-negative organisms
72
. Cefepime and 
carbapenems are resistant to the hydrolysis caused by these enzymes.  
           The main reason for the resistance of A.baumannii to carbapenem dugs is class D 
(OXA) carbapenemases . Acinetobacter strains also express Ambler class B MBLs, such 
as IMP, VIM, and SIM-1. They show high level of resistance to carbapenems and to 
other beta-lactam antibiotics except Aztreonam
73
.  
           Extended-spectrum beta-lactamases from the Ambler class A group have also been 
described for A. baumannii. 
74 75 
        S. maltophilia has an inducible, chromosomally encoded class D beta lactamase. 
They efficiently hydrolyze imipenem and is a Zinc metallo enzyme rather than a serine 
metallo enzyme. 
ACQUIRED RESISTANCE:  
             This may be due to mutation or attainment of resistance mechanism via 
horizontal gene transfer and can take place during improper antibiotic usage
 20
.  
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     Mutation leads to over expression of endogenous beta lactamases or efflux pumps, 
target site modifications, and reduced expression of specific porins. 
     Mutational derepression of AmpC enzyme is one of the frequent mechanisms of beta-
lactams. AmpC enzymes are not carbapenamases, but they posses low potential of 
carbapenem hydrolysis and their overproduction along with efflux pumps, overexpression 
and/or diminishes outer membrane permeability also may lead to carbapenem resistance. 
          Acquired beta lactamases are encoded by genes which are situated in transferable 
genetic elements such as plasmids or transposons frequently on integrons and also on 
mobile insertion sequences called ISCR elements. Occasionally resistance genes for other 
antibiotic classes are also located in the same integrons contributing to multi drug 
resistant phenotype 
20
.  
          Carbapenemases are of clinical importance because they inactivate carbapenem 
along with other beta lactam antibiotics. The class B carbapnemasess that bear Zn
2+ 
in 
their active center are most common and are called metallo-betalactamases(MBLs.). They 
hydrolyse all beta lactams except the monobactam, aztreonam and are the most important 
cause of high level carbapenem resistance 
13
. 
         The activity of class B MBLs are not inhibited by clavulanic acid and tazobactam, 
but they are inacivated by bivalent ionic chelators,
76 
 e.g. EDTA. IMP, VIM, SPM, AIM, 
NDM-1 and GIM type MBLs were identified in P. aeruginosa. 
           The first carbapenemase to be confirmed in P. aeruginosa was IMP-1 in Japan 
from carbapenem resistant clinical isolates from 1992 – 1994 77. VIM-1 carbapenamases 
52 
 
are found in nosocomial P.aeruginosa strains in Italy in 1997 
78
. GIM, AIM and NDM 
producing P.aeruginosa are reported in Germany, Australia and Serbia respectively 
76,79
. 
 
RESISTANCE TO FLUOROQUINOLONES: 
            Two mechanisms which leads to fluoroquinolone resistance in P.aeruginosa are 
Sstructural alteration in target enzymes and active efflux system.  
               DNA gyrase (GyrA and GyrB) is the primary target of fluoroquinolones in 
P.aeruginosa. This is due to point mutation in gyrA/gyrB genes which results in 
synthesis of modified topoisomerase II with reduced binding affinity to quinolone 
molecules. Modifications of a secondary target (topoisomerase IV) occur as a result of 
point mutations in parC and parE genes encoding ParC and ParE enzyme subunits, 
respectively 
80 81
. 
        In Acinetobacter strains resistance to flouroquinolones is mediated by mutation in 
gyrA and DNA topoisomerase mutations
 82
. 
RESISTANCE TO AMINOGLYCOSIDES:
83 
     Three different mechanisms are involved in the aminoglycoside resistance.  
1) Acetylation by aminoglycoside acetyltransferases (AACs) 
2) Adenylation by aminoglycoside nucleotidyltransferases (ANTs) 
3) Phoshphorylation by aminoglycoside phosphotidyl transferases. (APHs) 
Genes coding for AMEs are found on integrons. 
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Approaches to Overcoming Resistance: 
1. combination therapy 
2. using of antibiotic with an agent which overcome the antibiotic resistance 
mechanism 
3. Boosting of patients specific and non specific defence mechanism
8
  
 
3.7.  IDENTIFICATION OF NFGNB:
1 
          For the routine identification of NFGNB, there are different methods available 
which can be divided into: 
         A. Conventional tests 
         B. Commercial kit systems 
Conventional tests:
1 
             Different schemes are available for identification of NFGNB. The scheme for 
identification of the NFGNB depends on personal preference, past experience and the 
availability of the culture media required for identification. The schemes available are: 
1.  Weyant, Giraldi and Pickett Identification schemes 
 
                    These systems have largest databases available for identification. They are 
based on the identification charts originally derived by Elizabeth King at the CDC. 
2.  CDC scheme – Weyant and associates. 
                   This scheme consists of  
                            a. An identification key for gram-negative aerobes 
                            b. A set of 12 identification tables 
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                            c. A numerical code book by which derived biotype numbers can be                                
linked to species names 
           They also include procedures and media formulas for all the biochemical tests 
cited in the identification manual. The main disadvantage of this system is that it is too 
voluminous and simplification of the system has become essential for using it routinely     
3. The Giraldi scheme: 
 
                This is based on two fundamental principles: 
      a. The media and the tests are readily available in most clinical laboratories 
      b. Identification of most clinical isolates can be made in two stages – the first through 
the use of a primary battery of media and reactions that are sufficient in majority of the 
cases. A second set of reactions is then used, if identification using the primary set of 
reactions is not made. 
                    This system is also very complicated to be used routinely. However, the 
recent modification to this scheme is devised for the small and medium-sized laboratories 
and is simpler and more practical than the original scheme.   
4.  The Pickett scheme 
             The highlight of this scheme is that, it was designed to rapidly identify two of the 
most frequently isolated nonfermenters, namely Pseudomonas aeruginosa and 
Acinetobacter baumannii. If the isolates are other than these two common organisms, 
different tables are available for further identification, which are similar to the Weyant- 
CDC scheme. 
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Pratical approach to Identification of NFGNB 
This approach is designed by P.C. Schreckenberger. This scheme divides the clinically 
important NFGNB into four functional groups, based on motility and the ability to 
produce cytochrome oxidase. Further tests are then carried out and the organism can be 
identified upto species level. 
Advantages of this scheme are that  
a. This scheme is simple compared to other available schemes 
b. >95% of the NFGNB can be identified. 
c. Routine media are sufficient for isolation and identification  
 Computer- aided schemes 
             DOS and Windows based schemes are available. With the results of the 
biochemical tests, NFGNB can be identified using databases. 
Commercial kit based systems 
       Commonly used systems for the identification of NFGNB include : 
a. Oxi/Ferm Tube (Becton Dickinson Microbiology Systems) 
b. API 20E (BioMerieux) 
c. API 20NE (Biomerieux) 
d. Remel Uni-N/F System (Remel) 
e. Crystal Enteric / Nonfermenter System (Becton Dickinson Microbiology 
Systems) 
f. RapID NF Plus (Remel) 
g. Biolog system (Biolog) 
56 
 
 
Advantages of these packaged systems are: 
1. They are convenient to use, 
2. Have a long shelf life 
3. The need for fresh media and reagents is eliminated. 
4. They also provide standardized techniques that are accurate and give 
reproducible results equal to or better than conventional procedures. 
The problems in the use to these systems include: 
1. The organisms that exhibit weak or delayed biochemical activity produce false- 
negative reactions 
2. Many of these systems are designed inadequately, for cultivation of certain 
NFGNB 
3. Inclusion of some tests that is not applicable to identification of NFGNB 
 
3.8. TESTS FOR MBL CARBAPENEMASES: 
84 85
  
3.8.1PHENOTYPIC TESTS: 
3.8.1.1 MBL SCREENING: 
   Isolates resistant to either Imipenem or Meropenem or Ceftazidime are considered 
screening positive and subjected to confirmatory tests. Various confirmatory tests have 
been described- 
  1. Imipenem- EDTA combined disc test 
  2. Imipenem – EDTA double disc synergy test 
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  3. EDTA disc potentiation test 
  4. Modified Hodge test 
  5. MBL E-test 
  6. Carba NP test  
 
 3.8.1.2.  Imipenem- EDTA combined disc test:
86 87 
   
        Briefly, an overnight culture of an imipenem resistant clinical isolate was diluted 
with peptone water to 10
5
 CFU/mL and spread on Mueller-Hinton (MH) agar plate using 
cotton swab. Two IPM disks were placed on the surface of the agar at a distance of 4-5 
cm from each other. 5 μL of 750 μg/mL EDTA solution was then added to one of the 
IPM disks. The zone of  inhibition displayed around the IPM and the IPM-EDTA disks 
were compared after 14 to 16 hrs of incubation at 37
0
C 
      The difference of ≥7 mm between the inhibition zone diameter of the IPM-EDTA 
disk and that of IPM only disk was considered to be a positive for the presence of MBLs. 
88
.   
 
3.8.1.3. Imipenem EDTA disk synergy (EDS) test 
89
: 
     
               EDTA disk synergy (EDS) test is done by simultaneously testing two different 
β-lactams (imipenem and ceftazidime), for detection of metallo-β-lactamases in the 
imipenem resistant isolates.  
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           A 0.5 M EDTA solution was prepared by dissolving 186.1 g of disodium EDTA 
2H2O in 1,000 ml of distilled water. The pH was adjusted to 8.0 by using Sodium 
hydroxide and was sterilized by autoclaving. 
          An overnight liquid culture of the test isolate is adjusted to a turbidity of 0.5 
McFarland standard and spread on the surface of a MHA plate. A 10 μg imipenem disk 
and a 30 μg ceftazidime disk is placed on the agar. A blank disk (6 mm in diameter, 
Whatmann filter paper no. 1) was kept on the inner surface of the lid of the MHA plate 
and 10 μl of 0.5 M EDTA is added to it. This EDTA disk was then transferred to the 
surface of the agar and was kept 10 mm edge-to edge apart from the imipenem or 
ceftazidime disk. After incubating overnight at 37
o
C, the presence of an expanded growth 
inhibition zone between the two disks is interpreted as positive for MBL production 
 
 
3.8.1.4. EDTA disc potentiation using Ceftazidime, Ceftriaxone, Cefepime and 
Cefotaxime: 
               The test organism is inoculated on to plates with Mueller Hinton agar as 
described for the standard disc diffusion test. A blank filter paper disc is placed in the 
centre of the plate and the following discs: Ceftazidime (30 μg), Ceftriaxone (30 μg), 
Cefotaxime (30 μg), Cefepime (30 μg) are placed 25mm centre to centre from the blank 
disc. 10 μl of 0.5 M EDTA solution is added to the blank disc and the plate is incubated 
overnight at 35ºC. Enhancement of the zone of inhibition in the area between the EDTA 
disc and any one of the four discs in comparison with the zone of inhibition on the far 
side of the drug is interpreted as a positive result
 90
.  
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 Modified HODGE Test: 
91 
   
            The meropenem resistant strains were subjected to modified Hodge test for 
detecting carbapenemases. An overnight culture suspension of Escherichia coli ATCC 
25922 adjusted to 0.5 McFarland standard was inoculated using a sterile cotton swab on 
the surface of a Mueller-Hinton agar (MHA). After drying, 10 μg meropenem disk was 
placed at the center of the plate and the test strain was streaked from the edge of the disk 
to the periphery of the plate in four different directions. The plate was incubated 
overnight at 37
0C. The presence of a „cloverleaf shaped‟ zone of inhibition due to 
carbapenemase production by the test strain was considered as positive. 
     
MBL E-test 
92 93
:  
             An overnight culture of an clinical isolate was diluted in peptone water to a 
turbidity of a 0.5 McFarland standard. A cotton swab was then used to transfer the 
inoculum onto a MH agar plate. Once dried, an E-test MBL strip (Himedia , Mumbai, 
India) was applied onto the plate which was then incubated at 37
◦
C for 16 to 18 hrs to 
detect the presence of metallo enzymes. 
         Etest MBL strips contain increasing concentrations of imipenem (IP) on one end of 
the strip and imipenem overlaid with EDTA (IPI) on the other. The EDTA chelates the 
zinc ions required by MBLs to catalyse the hydrolysis of imipenem and meropenem, 
thereby inhibiting MBL activity. A reduction in the imipenem MIC in the presence of 
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EDTA of greater than or equal to eight-fold (IP/IPI ≥ 8) is interpreted as indicating MBL 
activity. 
Carba NP test: 
94 95 96 
         The Carba NP test is a novel phenotypic method developed for carbapenemase 
detection. It is based on in vitro hydrolysis of imipenem by a bacterial lysate, which is 
detected by changes in pH values using the indicator phenol red (red to yellow/orange). It 
was reported to be 100% sensitive and specific for Enterobacteriaceae and 100% specific 
and 94.4% sensitive for Pseudomonas spp. harboring carbapenemases. 
          This test is based on biochemical detection of the hydrolysis of the beta-lactam ring 
of a carbapenem, imipenem, followed by change in the colour of a pH indicator. This test 
was performed on isolates grown on Mueller-Hinton agar plates at 37°C for 18 to 22 h .  
Isolated colonies are mixed with a solution of Imipenem and phenol red indicator 
solution and incubated at 37°C for a maximum of 2 h. If Carbapenemase producing 
organisms are present the Carbapenemase will hydrolyse the Imipenem, resulting in a 
decrease in pH. This is detected by a colour change of phenol red solution to yellow-
orange. 
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                MATERIALS AND METHODS 
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                         4.0  MATERIALS AND METHODS 
 
4.1.1  Source of data 
         NFGNB isolated from heterogenous clinical samples like urine, blood, pus, sputum, 
pleural fluid, peritoneal fluid, blood and CSF received for culture and sensitivity in 
department of microbiology and environmental samples from various ICUs and burns 
unit in chennai medical college hospital and research centre,  Trichy  were included in the 
study. 
4.1.2  Duration of data collection: 
            10 months (August 2014 to May 2015)  
4.1.3 Sample size: 
         172 Non repetitive non fermenter isolates 
4.1.4 Inclusion criteria: 
1. Isolates from all clinical samples which were identified as Non-fermenting Gram 
negative bacilli as per recommended standard methods. 
4.1.5 Exclusion criteria: 
1. Mixed growth of > 3 types (probably contaminated sample) 
2. Isolates from improperly collected samples. 
4.1.6 Study design:  
   Hospital based Cross sectional descriptive study.  
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4.1.7 Data Collection: 
        All data were entered into a Data Collection proforma Sheet and were entered into 
SPSS data sheet. 
4.1.8. Satistical Methods: 
            Statistical analysis were done using SPSS software version 22.0 
4.2. Ethical committee approval:  
        Institutional Ethical committee approval was obtained before the start of the 
dissertation and the approval certificate is enclosed. 
 4.3. COLLECTION OF VARIOUS SAMPLES 
4.3.1.  RESPIRATORY TRACT SAMPLES: 
         Sputum sample was collected in a wide neck dry sterile container after proper 
instruction to the patient. Using the inoculation loop purulent portion of the sputum is 
transferred to the slide and a thin smear was made. The smear was then air dried, fixed 
and stained by the gram technique. Samples were then microscopically examined to 
assess contamination with upper respiratory tract secretions during collection. The 
sample is considered to be minimally contaminated if 25 pus cells and <10 epithelial 
cells/hpf. 
Significance was laid to inflammatory cell response and predominance of bacteria 
in the pus cells in the gram stain preparation. 
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The endotracheal tube tips were received in sterile containers. The tips including 
the bore were washed with ~0.5ml sterile peptone water. This was vortexed thoroughly 
and the resulting suspension was used to inoculate the plate for culture. 
All these respiratory samples were inoculated on sheep blood agar (BA), Mac 
Conkey Agar (MA) and Chocolate Agar (CA). All plates were incubated overnight at 
37°C and observed for growth up to 48 hrs. 
 
4.3.2. PUS & WOUND SWABS: 
                Using a sterile technique, pus was aspirated with syringe and needle or 
collected from a drainage tube preferably up to 5 ml and transferred to a leak-proof sterile 
container.  
               For wound swab, the area was wiped with sterile normal saline or 70% alcohol 
and the swab was taken along the leading edge of the wound. Two swabs are taken. One 
swab was used for culture and other for direct smear examination by Gram‟s stain. 
         These samples were inoculated on BA, MA, which were incubated overnight at 
37
0
C and observed for growth for 48 hrs. 
4.3.3. URINE: 
            After washing their hands with soap and water, the female patient was instructed 
to cleanse the area around the urethral opening with clean water, dry the area with a 
sterile gauze pad, and collect the urine with the labia held apart. The same was done for 
the male patients after retracting the foreskin. 
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             Clean catch midstream urine is collected in a sterile, dry, leak proof, transparent 
screw capped container. In case of indwelling catheters, the collection port was 
disinfected and 5 to 10ml of urine was aspirated with syringe and needle. The urine was 
processed within 2 hrs.  
           The gross appearance of the urine was noted.  Wet film examination of the urine 
was done and the pus cells and bacteria were looked for. 
           A standard inoculation loop of diameter 4mm which delivers 10µl of urine was 
streaked in NA, Mac, and BA plates and incubated at 37
0
c and observed for growth for 
24 hours. Only those isolates found significant in semi quantitative culture of urine were 
included in the study. 
 
4.3.4. BLOOD:   
        A brain heart infusion broth was used for blood culture. The bottle was examined 
daily for turbidity and subculture was made at regular intervals on to BA, MA and any 
growth was processed further for identification. NFGNB grown in blood culture were 
included if they grew in first two days of incubation of blood culture bottles.  
 
4.3.5. ENVIRONMENTAL SAMPLES: 
             Samples from RICU, IMCU, Post operative ICU, PICU, Burns unit were taken. 
Samples from Staff hands, bed rails, wash basin sink, disinfectant solution, saline, 
nebulizer, oxygen mask, ambu mask, door handle were taken using saline moistened 
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sterile swabs. Tap water was collected in a sterile bottle after cleaning the mouth of the 
tap and allowing some water to flow out. The swabs were kept in nutrient broth overnight 
and inoculated in selective media for Pseudomonas aeruginosa and Acinetobacter, 
Pseudomonas isolation agar (Himedia Mumbai) and Leeds acinetobacter media (Himedia 
Mumbai) respectively.  
       Samples were collected under aseptic precaution and transported to the lab. 
 
4.4. PROCESSING OF SAMPLES: 
           The study is conducted as follows:  
 
                                     Grams Stain  
                                          
                                        Culture                  
     
          NA, MAC, BAP                                                          
 
                              Incubate aerobically at 37
0
 C for 24 hours            
                           
     Non lactose fermenting colonies were inoculated on Triple Sugar Iron agar (TSI) 
medium. .                  
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4.5. IDENTIFICATION: 
     The most commonly isolated nonfermenters i.e., P.aeruginosa, A.baumannii and 
S.maltophila were identified by the following characteristics: 
1
 
 
4.5.1 IDENIFICATION OF PSEUDOMONAS AERUGINOSA:   
        Pseudomonas aeruginosa was identified by the presence of: 
1. Large flat non-lactose fermenting colonies on MA 
2. Large, flat, sometimes ß- haemolytic colonies on BA 
3. Grape-like odour 
4. Production of pyocyanin, pyoverdin, pyorubin pigment on NA, BA  
5. Oxidase test positive. 
6. Positive for motility 
7. Growth at 42
0
C 
4.5.2. IDENIFICATION OF ACINETOBACTER BAUMANNII:   
      Acinetobacter baumannii was identified by following characteristics:
1 
1. Coccoid or coccobacillary appearance on Gram stain 
2. Medium sized, smooth, convex colonies with a slightly pinkish tint on MA 
3. Oxidase test negative 
4. Rapid utilization of 10% lactose with acid production 
5. Growth at 42
0
C 
6. Non- motile 
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4.5.3. IDENIFICATION OF STENOTROPHOMONAS MALTOPHILA:   
     Stenotrophomonas maltophila was identified by:
1 
1. Oxidase test negative 
2. Production of acid in OF maltose 
3. Lysine decarboxylase positive 
 
        If any other organisms were isolated other than the above, they were further 
identified based on the scheme of identification given by P.C. Schreckenberger. The 
organisms are grouped into four major groups based on Oxidase test and motility. 
   Further identification was done by using the following tests:  
1. Hugh Leifson‟s Oxidative Fermentative test 
2. Nitrate test 
3. Indole test 
4. Citrate utilisation test 
5. Urease test 
6. Triple Sugar Iron (TSI) agar 
7. Arginine dihydrolase test 
8. Lysine decarboxylase 
9. OF sugars of mannitol, lactose and dextrose 
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        Figure 1: Scheme used in the study for identification of nonfermenting gram-
negative bacilli * Burkholderia species vary in their oxidase reaction: Burkholderia 
gladioli is oxidase -ve, B. cepacia complex is weak +ve and B. pseudomallei is oxidase 
+ve, OF: Oxidation-fermentation
2
. 
 
4.5.4. IDENTIFICATION OF ISOLATES FROM ENVIRONMENTAL SAMPLES: 
       Pseudomonas aeruginosa colonies will appear green to blue-green, in Pseudomonas 
isolation agar with pigment that diffuses into the medium 
97
.  
    Acinetobacter species colonies will appear as pink mucoid colonies in Leeds 
Acinetobacter medium with pink color diffused into the medium 
98 
.
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4.6. ANTIBIOTIC SUSCEPTIBILITY TESTING  
               Antimicrobial susceptibility testing was performed by using Kirby Bauer disc 
diffusion technique according to CLSI 2014 guidelines. The following antibiotics were 
used for susceptibility testing: Ceftazidime, Cefepime, Ciprofloxacin, Levofloxacin, 
Gentamicin, Amikacin, Piperacillin-Tazobactum, Meropenem, Imipenem,Aztreonam. 
The P.aeruginosa ATCC 27853 strain was used as the quality control. All the discs were 
procured commercially (Hi-media laboratories limited).The diameter of the zone of 
inhibition was measured and interpreted according to the CLSI 2014 guidelines 
91
. 
                  Imipenem resistant isolates (≤15 for P.aeruginosa and ≤18 for Acinetobacter 
baumannii) were further subjected to the following tests for Metallo beta lactamase 
detection. 
 4.7 PHENOTYPIC METHODS FOR DETECTION OF MBL: 
   4.7.1. IMIPENEM-EDTA COMBINED DISC TEST: 
      One imipenem (10µg) disc and one imipenem-EDTA disc were placed on the surface 
of an agar plate. Plates were incubated for 16 to 18 hours at 35˚C. If zone of inhibition of 
imipenem- EDTA disc was ≥ 7 mm more than that of imipenem disc alone, it was 
considered MBL positive. 
4.7.2. IMIPENEM EDTA DISK SYNERGY (EDS) TEST: 
                 EDTA disk synergy (EDS) test was done with simultaneous testing of two 
different β-lactams (imipenem and ceftazidime), for detection of metallo-β-lactamases in 
the imipenem resistant isolates.  
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           A 0.5 M EDTA solution was prepared by dissolving 186.1 g of disodium EDTA 
2H2O in 1,000 ml of distilled water. The pH was adjusted to 8.0 by using NaOH and was 
sterilized by autoclaving. An overnight liquid culture of the test isolate was adjusted to a 
turbidity of 0.5 McFarland standard and spread on the surface of a MHA plate. A 10 μg 
imipenem disk or 30 μg ceftazidime disc was placed on the agar. A blank disk (6 mm in 
diameter, Whatmann filter paper no. 1 was kept on the inner surface of the lid of the 
MHA plate and 10 μl of 0.5 M EDTA was added to it. This EDTA disk was then 
transferred to the surface of the agar and was kept 10 mm edge-to edge apart from the 
imipenem or ceftazidime disk. After incubating overnight at 37
o
C, the presence of an 
expanded growth inhibition zone between the two disks was interpreted as positive for 
MBL production 
 
4.7.3.MBL E-TEST: 
         A 0.5 McFarland‟s suspension of the each isolate was made separately and 
inoculated on a plate of MHA. The Etest MBL strip containing an antibiotic 
concentration gradient for imipenem (IP) alone of 4 to 256 μg/mL and imipenem in 
combination with a fixed concentration of EDTA (IPI) gradient of 1 to 64 μg/mL is 
applied on the plate. The plate was then incubated at 37 °C for 24 h according to the 
manufacturer‟s instructions (Etest MBL). MIC ratio of IP (Imipenem)/IPI (Imipenem-
EDTA) of > 8 or > 3 log 2 dilutions, a phantom zone or a synergistic zone indicated MBL 
production 
99 
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4.8. MBL GENE IDENTIFICATION:  
       blaVIM and blaIMP gene detection was done for ten isolates imipenem resistant 
P.aeruginosa and A.baumannii using multiplex PCR in Chromopark Research centre, 
62-B, near NKR college, Trichy main road, Namakkal-637001, Tamil Nadu. 
 
    Procedure: 
Multiplex PCR amplification for the simultaneous detection of blaIMP and 
blaVIM metallo beta -lactamase genes was carried out using Taq DNA polymerase, 
deoxynucleoside triphosphate and gene-specific primers (shrimpex, India). 
The composition of the reaction mixture was as follows: Each PCR reaction 
mixture (25μl) contained 2μl of template DNA (plasmid DNA), 10 μl of 10 X PCR 
buffer, 0.5 μl of (0.5 µM) each of the primers and 9.0 μl of molecular grade water. 
The PCR program was performed in a Thermal Cycler and it consisted of an initial 
incubation of 10 min at 37°C and an initial denaturation step at 94°C for 5 min, followed 
by 30 cycles of DNA denaturation at 94°C for 1 min, primer annealing at 54°C for 1 min, 
and primer extension at 72°C for 1.5 min. Following PCR, aliquots (20 μl) of the reaction 
mixtures were analyzed by electrophoresis on a 1.5% Agarose gel, containing ethidium 
bromide (0.2 mg/ml), in the presence of an appropriate DNA molecular weight marker. 
Then observe the amplification bands under UV Transilluminater and detection of 
resistance genes with the use of marker. 
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             5.0   RESULTS 
The study entitled “IDENTIFICATION OF NON FERMENTING GRAM NEGATIVE 
BACILLI FROM CLINICAL, ENVIRONMENTAL SAMPLES, THEIR 
ANTIMICROBIAL RESISTANCE AND DETECTION OF blaVIM/blaIMP GENES IN 
IMIPENEM RESISTANT ISOLATES was carried out in the department of microbiology 
, Chennai medical College Hospital and Research centre. 
                A total of 172 NFGNB isolates were identified from clinical samples processed 
during a period of 10 months from August 2014 to May 2015                                                     
5.1.Age wise distribution: 
          The agewise distribution of NFGNB is shown in Table  
TABLE- 5:  AGE WISE DISRIBUTION 
        
 
 
 
           
 
AGE IN 
YEARS 
NO.OF  
SAMPLES 
PERCENTAGE 
1 – 10 7 4.1 
11 – 20 12 7.0 
21-30 19 11.0 
31-40 32 18.6 
41-50 30 17.4 
51-60 28 16.3 
>60 44 25.6 
Total 172 100.0 
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        The youngest patient was 6yr old and the oldest patient was 82yrs old. The age 
group above 60 years accounted for 25.6% which is the highest percentage followed by 
31-40(18.6%),41-50(17.4%) and 51-60(16.3%) and the least percentage was seen below 
10 years of age.   
5.2. SEX WISE DISTRIBUTION  
         Out of 172 samples isolated 112(64.1%) were from males, 60(34.9%) were from 
females. Figure 1 depicts sex wise distribution of  NFGNB. Sample wise distribution of 
isolates is depicted in figure 2.  
Figure 1: Sex wise distribution of NFGNB          
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       5.3. SAMPLE WISE  DISTRIBUTION: 
Figure 2: Sample wise distribution of NFGNB 
            
 
The above figure shows the sample wise distribution of NFGNB. Pus was the 
commonest sample from which NFGNB were isolated the most 52.3% followed by 
sputum (20.9%), urine (9.9%), ear swab (6.4%), ET tip (5.2%), blood (4.7%) and drain 
tip (0.6%). 
Out of 172 isolates, the commonest was P.aeruginosa (100:59%) followed by 
A.baumannii (35:20.3%), A.lwoffii (18:10%), P.fluorescens (12:7%),   Flavobacterium 
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meningosepticum and Achromobacter species (2 no.)  and one isolate each of Shewanella 
and P.stutzeri, Stenotrophomonas maltophila. 
Figure 3: Distribution of NFGNB (Number & Percentage) 
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5.5. SAMPLE WISE ANALYSIS OF ISOALTES: 
Figure 4: Sample wise analysis of Isolates 
 
 
  The above chart depicts the number of different isolates from various clinical 
samples. P.aeruginosa was mostly isolated from pus sample (50%), followed by sputum 
(23%), urine (11%), ET tube(11%), ear swab(6%), and blood. 
 P.fluorescens was mostly isolated from Pus(66%), followed by Sputum(16%) and 
ear swab(16%) 
    A.baumannii was isolated most commonly from pus(51.4%), followed by 
blood(15.7%) and urine(14.2%)  and sputum (14.2%) 
Most of the A.lwoffii were isolated from pus(61%),ear swa(16.6%), sputum, urine 
and drain tip. 
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Flavobacterium sp. and Achromobacter were identified only in sputum and 
Shewanella sp. and P.stutzeri were isolated only in pus samples. 
5.6. SAMPLE WISE SENSITIVITY PATTERN OF P.AERUGINOSA ISOLATES: 
Table 6: Sample wise sensitivity pattern of P.aeruginosa isolates 
 
Antibiotics 
PUS 
n=50 
SPUTUM 
   n=23 
URINE 
n=11 
BLOOD 
n=2 
EAR 
SWAB 
  n=6 
   ET 
Tube 
 n=7 
S  
(%) 
R 
(%) 
S  
(%) 
R 
(%) 
S  
(%) 
R 
 (%) 
S  
(in 
no.) 
R 
(in 
no.) 
S  
(in 
no.) 
R 
(in 
no.) 
S  
(in 
no.
) 
R 
(in 
no.
) 
Ciprofloxacin 60 40 91 9 81 19 2 0 5 1 7 1 
Levofloxacin 60 40 86 14 81 19 1 1 5 1 7 1 
Amikacin 64 36 100 0 81 19 1 1 5 1 6 2 
Gentamicin 56 44 91 9 72 28 1 1 6 0 4 4 
Ceftazidime 60 40 86 14 72 28 1 1 6 0 7 1 
Cefepime 64  36 91 9 81 19 2 0 6 0 6 2 
Pipericillin 
Tazobactum 
76 24 95 5 81 19 2 0 6 0 7 1 
Aztreonam 74 26 95 5 81 19 1 1 6 0 8 0 
Imipenem 78 22 100 0 72 28 2 0 6 0 7 1 
Meropenem 78 22 95 5 72 28 2 0 6 0 7 1 
 
             P.aeruginosa showed the highest sensitivity to imipenem(78%) and 
meropenem(78%) in pus samples, to Amikacin(100%) in sputum samples, to 
Fluoroquinolones, cefepime, pipericillin-Tazobactum, Aztreonam in urine samples.          
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 5.7. SAMPLE WISE SENSITIVITY PATTERN OF A.BAUMANNII  ISOLATES: 
Table 7: Sample wise sensitivity pattern of A.baumannii isolates 
 
 
 
Antibiotics 
PUS 
n=18 
SPUTUM 
   n=5 
URINE 
n=5 
BLOOD 
n=6 
   ET 
Tube 
 n=1 
S  
(%) 
R 
(%) 
S  
(in 
no.) 
R 
(in 
no.) 
S  
(in 
no.) 
R 
(in 
no.) 
S  
(in 
no.) 
R 
(in 
no.) 
S  
(in 
no.) 
R 
(in 
no.) 
Ciprofloxacin 44 56 4 1 3 2 4 2 1 0 
Levofloxacin 44 56 3 2 3 2 5 1 0 1 
Amikacin 38 62 4 1 4 1 5 1 0 1 
Gentamicin 38 62 3 2 3 2 5 1 0 1 
Ceftazidime 16 84 3 2 3 2 4 2 0 1 
Cefepime 22 77 2 3 2 3 5 1 0 1 
Pipericillin 
Tazobactum 
22 77 3 2 3 2 6 0 0 1 
Aztreonam 77 22 5 0 5 0 5 1 1 0 
Imipenem 33 67 2 3 2 3 6 0 0 1 
Meropenem 33 67 2 3 2 3 6 0 0 1 
 
                  The above table depicts the number of A.baumanii isolated from each sample 
and their susceptibility and resistance rates in relation to each sample.  
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5.9.  ANTIBIOGRAM OF P.AERUGINOSA ISOALTES: 
Figure 5: Antibiotic susceptibility pattern of P.aeroginosa isolates from all 
Clinical samples 
 
Eighty six percentage of isolates were sensitive to imipenem, followed by 
piperacillin tazobactum and meropenem (85%). 74% of isolates were sensitive to 
ciprofloxacin and cefepime and 76% sensitivity to amikacin. A sensitivity of 69% and 
68% were observed for levofloxacin and gentamycin respectively. The most effective 
drug in our study was imipenem. 
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5.10. ANTIBIOGRAM OF A.BAUMANNII ISOLATES: 
Figure 6: Antibiotic susceptibility pattern of A.baumanii isolates from all 
clinical samples 
 
 
Eighty percent of the isolates were sensitive to Aztreonam. Sensitivity of the drugs 
gentamycin, levofloxacin, ciprofloxacin and meropenem were 52%, 55%, 49% and 49% 
respectively. Resistant was observed more for the drugs ceftazidime (63%), cefipime 
(62%), amikacin (57%) and imipenem (57%), ciprofloxacin (51%) and meropenem 
(51%). 
           Among 100 P.aeruginosa isolates, 14 (14%) were resistant to imipenem, and 15 
isolates (15%) were resistant to meropenem. Among 35 A.baumannii isolates, 20 (57%) 
were resistant to imipenem and 18 (51%) were resistant to meropenem. These isolates 
were further tested by phenotypic methods for detection of MBL production like 
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combined disc test (imipenem/imipenem+EDTA), double disc synergy test ans MBL E 
test (IP-IPE) 
5.11. PHENOTYPIC METHODS FOR MBL DETECTION 
The different phenotypic methods for MBL detection is shown in Table 8.   
 
Table 8: Phenotypic methods for MBL detection 
          Test 
 
no. of isolates 
 tested 
Isolates 
positive 
Combined disc test 10 6 
Disc synergy test 10 8 
MIC E-strip 10 10 
  
Three phenotypic tests were performed for the detection of Metallo bta lactamase 
among ten imipenem resistant isolates. (3-P.aeruginosa and 7-A.baumanii) In that, 6 
isolates were positive for MBL in combined disc test, and 8 showed positivity for MBL 
in double disc synergy test and all the 10 isolate were MBL positive in MBL E-test. 
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 5.12 Genotype of MBL producing isolates: 
                   Genotyping for the detection of blaIMP, blaVIM genes was performed for the ten 
isolates which showed presence of MBL in the above phenotypic tests using multiplex 
PCR. The results of the test are depicted in the following figure 7. 
Figure 7: Number of blaIMP, blaVIM genes among Imipenem resistant isolates 
            
 
           
Among ten phenotypically confirmed isolates, blaIMP gene was detected in 7 
isolates and blaVIM gene was detected in 3 isolates and both the genes were present in 1 
isolate.  
Among three imipenem resistant P.aeruginosa isolates, all the three isolates 
possessed blaIMP  gene. None of the isolates possessed blaVIM gene. Figure 8 depicts 
number of blaIMP, blaVIM genes among Imipenem resistant P.aeroginosa isolates. 
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Figure 8: Number of blaIMP, blaVIM genes among Imipenem resistant 
P.aeroginosa isolates 
              
                         
Among seven imipenem resistant A.baumannii isolates, four  possesed blaIMP gene 
and , three isolates possesed blaVIM gene and one  possesed both blaVIM gene and blaIMP 
gene. Figure 9 depicts number of blaIMP, blaVIM genes among Imipenem resistant 
A.baumanii isolates. 
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Figure 9: Number of blaIMP, blaVIM genes among Imipenem resistant 
A.baumanii isolates 
               
 
 
             5.13. ENVIRONMENTAL SAMPLES: 
         Among sixty environmental samples, P.aeruinosa was isolated in 5 sites including 
SICU tap water, sink, Post operative ward door handle, sink, burns ward door handle and 
Acinetobater baumannii was isolates from two sites including ICU bed rails and RICU 
sink. 
          All strains isolated were sensitive strains.  
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Fig 10: Pyocyanin pigment of  P.aeruginosa in Pseudomonas isolation agar 
 
 
Fig 11: Biochemical reactions of  P.aeruginosa 
OF glucose showing fermentative reaction 
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Indole – Negative; TSI – Alkaline slant/No change;                                                          
Citrate Utilised;  Mannitol- Not fermented 
 
 
Fig 11: Acinetobacter baumanii on Mac conkey plate showing pinkish tint 
 
 
 
Fig 12: Biochemical reactions of A.baumanii 
Arginine dihydrolase – Positive ; 10% lactose - fermented 
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           Fig 13: Yellow pigment of Flavobacterium species in Muller Hinton plate 
 
 
Fig 14: Formation of Hydrogen sulfide in TSI agar by H2S producing Shewanella species 
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Fig 15: EDTA DOUBLE DISC SYNERGY TEST 
                Enhancement of zone towards EDTA disc 
                     E – EDTA disc 
                     P – Plain disc 
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Fig 16: MBL POSITIVE TEST ISOLATE 
       IPM         =    > 8, MBL POSITIVE 
                                   IPM+EDTA 
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                                                  6.0.  DISCUSSION 
 
               NFGNB are known to cause hospital acquired infections and opportunistic 
infections. The multidrug resistant organisms have increased due to widespread and 
indiscriminate use of antibiotics. This results in increased economic burden, duration of 
hospital stay and increased mortality and morbidity.  
             In this study, NFGNB were identified and their mechanisms of resistance to 
imipenem and meropenem drugs were detected. 
   6.1. AGE WISE DISTRIBUTION: 
        In our study the highest percentage was seen in the age group above 60 years which 
is 25.6% which is similar to other studies conducted by Kalidas Rit et al 
4
 in Kolkata in 
2013 where 72% of the patients were adults over 45 years of age and a study by 
Mohammed Rahbar 
5
 where majority of the patients (70%) were adults and study by 
Meenakumari et al 
100
 where 90% were adults. This could be due to sub normal immune 
system.  
    But this is in discordance with a study by Chander Anil et al in 2013 
101 
and a study by 
Rashid et al 
102
 where the highest percentage is seen in the age group between 21 to 40 
years. 
  
 
 6.2. RISK FACTORS: 
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         The various risk factors observed in our study in decreasing order of frequency are 
      1. Urinary catheterization -35% 
      2. Diabetes Mellitus – 12% 
      3. Stay in ICU – 12% 
      4. Surgery – 11% 
      5. Burns – 6% 
      6. Mechanical ventilation – 5%       
      7. Prolonged hospital stay - 5.2% 
      8. Trauma – 2% 
              The percentage of risk factor varies in a study by Mohammed Rahbar 
5
 where 
69% had history of invasive procedures, 56.9% had previous history of hospitalization, 
39% were under mechanical ventilation, 38% of patients were hospitalized in ICU. 
            Another study by Mohanasundaram 
103
 in 2010 revealed the following risk 
factors.  
              24% had previous surgery, (19.4%) Road traffic accident, 13.5% had underlying 
renal disease and diabetes mellitus, 11% with underlying respiratory disease and (6%) 
burns. 
           A study by Kalidas Rit et al, 
4
 showed that the various risk factors involved are 
connection to ventilator, history of invasive procedures, steroid usage, under 
immunosuppressive therapy. The percentage was not mentioned. 
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6.3. SEX WISE DISTRIBUTION: 
        In our study males (64.1%) are more commonly affected than the females (34.9%).  
Similar observation was made in other studies conducted by Murugan 2010 
104
 where the 
male to female ratio was 3:1 and in a study by Kalidas et al 
4
 55% were males and 45% 
were females and in a study in 2012 by Piyush 
105
 71.5% were males and 28.5% were 
females. 
 6.4. SAMPLE WISE DISTRIBUTION:     
         In the present study, NFGNBS were most commonly isolated from pus samples 
(52.3%) followed by sputum (20.9%), urine (9.9%), ear swab (6.4%), ET tip (5.2%), 
blood (4.7%) and drain tip (0.5%). This is in concordance with a study conducted in 2009 
in Kolar, India wherein NFGNBs were most commonly isolated from pus samples. Out 
of 193 samples, 120(62.2%) isolates of NFGNB were from pus samples 
2
.  Another study 
conducted in Belgaum in 2007 also showed that maximum number of NFGNB were from 
pus samples (58.4%) 
106
.  
            But it is discordant with the study carried out by Meenakumari et al 
100
 in 2011 
which showed most of the NFGNBs were from respiratory samples(52.9% )and only 
9.8% were from pus samples and a study by Mohammad Rahbar et al 
5
 in 2010 where 
34% was from tracheal aspirates. This may be due to nature of selection of samples. 
         
6.5. ISOLATE WISE DISTRIBUTION: 
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             In our study P.aeruginosa (59%) was the most common organism isolated from 
the clinical samples, followed by A.baumannii (21%), A.lwoffii (18:10%), P.fluorescens 
(12:7%),   Flavobacterium meningosepticum and Achromobacter species (2 no.)  and one 
isolate each of Shewanella, P.stutzeri, and Stenotrophomonas maltophila. This result is in 
concordance with a study conducted by Kaidas Rit  et al 
4
, 2013 where the predominant 
isolate was P.aeruginosa (50.2%) followed by A.baumanii (24.8%), Acinetobacter lowffii 
(5.47%), Pseudomonas fluorescens (1.49%), Pseudomonas stutzeri (1.99%),.  
        Other studies showing similar results include study by Chawla K et al 
3
 in 2013, 
where 56.7% isolates were P.aeruginosa and 39.3% were Acinetobacter sp and a study 
by Gokale in 2012 
 106 
where P.aeruginosa constituted 82.3% and A.baumannii 15.4%. 
 
6.6. SAMPLE WISE DISTRIBUTION OF ISOLATES AND THEIR 
ANTIBIOGRAM: 
           NFGNB shows a wide spectrum of antibiotic susceptibility.  
6.6.1. Pus sample : 
      In this study, P.aeruginosa(55.5%) and A.baumannii(20%) were the most common 
isolates from pus samples. This is similar to the study by Rashid et al,.
102
 where 55.1% of 
P.aeruginosa isolates were from pus samples and a study by Malini et al 
4 
, where 
P.aeruginosa and A.baumannii were the predominant isolates from pus samples.  
        In our study, P.aeruginosa showed the highest sensitivity to imipenem(78%) and 
meropenem(78%) followed by Pipericillin Tazobactum(76%) and Aztreonam (74%) and 
99 
 
more resistance was observed to Gentamicin(44%) followed by ceftazidime (40%), 
Ciprofloxacin(40%) and levofloxacin(40%) 
              Study by Rashid et al 
102
 showed P.aeruginosa from pus samples showed 100% 
resistant to azithromycin (100%), ceftazidme(86%),ciprofloxacin(75%) and least resistant 
to imipenem (3%) 
               A.baumanii showed more sensitivity to Aztreonam(77%) and more resistant to 
ceftazidime followed by imipenem(77%) and meropenem(67%) 
6.6.2.Urine samples : 
        In our study, the predominant isolate was P.aeruginosa(11%) followed by 
A.baumannii(14.2%). This is similar to the study conducted in Manipal in 2011 by 
Shobha 
6
 where the commonest isolate was P.aeruginosa (7.6%), followed by 
Acinetobacter sp.(1.8%). 
      In our study P.aeruginosa 81% isolates were sensitive to Amikacin, Aztreonam, 
Ciprofloxacin, Levofloxacin, Pipericillin-Tazobactam, and 72% isolates sensitive to 
imipenen. The sensitivity pattern varies in a study at Manipal 
2
 where the isolate is only 
42% sensitive to Gentamicin, 36% sensitive to Ceftazidime and 100% resistant to 
Aztreonam. 
          In our study, A.baumannii showed 100% sensitivity to Aztreonam which is in 
discordant with the study at Manipal 
2
 where none of the isolates were sensitive to 
Aztreonam. 
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6.6.3.Respiratory samples: 
           Out of 45 samples from respiratory tract, 36 sputum and 9 endotracheal tube tips, 
the predominant isolate  in our study is P.aeruginosa (68%) followed by A.baumannii 
(13%). 
         This is in discordant with a study by Malini et al,
2
 where the predominant 
respiratory pathogen is A.baumannii (40%) 
       In our study the most active drug against P.aeruginosa from sputum sample was 
Amikacin (100%) followed by Pipericillin-Tazobactam (95%). Study by Piyush 
105
 in 
Allahabad showed the most active antibiotic is Pipericillin-Tazobactam (91%) followed 
by Imipenam (89%) 
       But a study by Rashid et al 
102
 showed that 100% of P.aeruginosa from tracheal 
aspirates were resistant to amikacin, ciprofloxacin, and ceftazidime. 
  
 
6.6.4.Ear swab: 
      In our study the most common isolate from ear swab is P.aeruginosa (12%). The rate 
of resistance to ciprofloxacin, amikacin is 16.6%. This result is similar to the study by 
Rashid et al 
102
 were 10.5% of P.aeruginosa were isolated from aural swabs. The rate of 
resistance to ciprofloxacin and amikacin is 13.3% and 9.7% respectively.   
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 6.7. Overall Antibiotic susceptibility of P.aeruginosa: 
           In our study, among Pseudomoans aeruginosa species, imipenem, meropenem, 
pipercillin-tazobactum, Aztreonam, cefepime showed highest activity with overall 
susceptibility of 86%, 85%, 85%, 83%, 74% respectively.  The sensitivity to imipenem is 
similar to study conducted by Mohammad Rahbar 2010 
5
 where it was 78.9%, and 94.2% 
in a study by Malini et al in the year 2009 
2
. 
       This result was in discordance with a study conducted in 2013 by Juyal,
7
 where the 
highest sensitivity was observed with Amikacin (72.3%). 
         In our study the highest resistance was recorded for gentamicin (32%), levofloxacin 
(31%). But in a study by Tripathi et al 
105
 in 2010, ceftazidime showed highest resistance 
(36%). 
6.8. Overall Antibiotic susceptibility of Acinetobacter baumannii: 
          In our study, A.baumannii showed resistance to most of the antibiotics used. The 
most active antibiotic against A.baumanii was Aztreonam and 80% of isolates were 
susceptibile to this antibiotic. The highest resistance was seen to drugs like Amikacin 
(57%), Imipenem (57%) and Pipericillin Tazobactum(54%) . This is in discordance to 
other studies by Mohammad Rahbar 
5
 in 2010 where imipenem(95.5%) was the most 
active drug and 90% of the isolates were resistant to Aztreonam. In another study by 
Kalidas Rit et al in 2013
4
 where the most effective drug was Imipenem with susceptibility 
of  95%. 
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6.9. MBL Detection: 
              Active surveillance of multi drug resistant organism is very important for 
provision of effective health care. MBLs are emerging as one of the most troublesome 
resistant mechanisms because they limit our treatment options and also the genes 
responsible for resistance is carried on highly mobile elements resulting in early 
dissemination. 
        In present study, MBL detection was performed for 10 imipenem (3-P.aeruginosa 
and 7-A.baumanii) resistant isolates, using three different phenotypic methods like 
combined disc test (imipenem/imipenem+EDTA), double disc synergy test and MBL E-
test (IP-IPE). Genotypic detection of blaVIM and blaIMP gene was done using multiplex 
PCR. 
6.9.1. Sensitivity of different Phenotypic tests: 
                In our study, screening for MBL showed that 6 isolate were positive for MBL 
in combined disc test, and 8 showed positivity for MBL in double disc synergy test and 
all the 10 isolate were MBL positive in MBL E-test. Genotypic detection of MBL genes 
using multiplex PCR confirmed the presence of MBL genes in all the ten isolates. 
                 This variation between phenotypic and molecular characterization is 
previously documented in studies conducted by Saber Yousefi in Iran in 2010 
107
, where 
39 isolates were positive for MBL by double disc synergy test but PCR confirmed the 
presence of MBL gene only in 24 isolates.  
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         Another study by Pena et al in Portugal in 2008 
108 
showed that 40 isolates were 
MBL positive in combined disc method but PCR results showed only 26 isolates were 
positive for MBL gene. The reason for this inconsistency is unknown. The possible 
reasons could be the interference of other resistance mechanisms with MBL detection by 
phenotypic methods or presence of other unrecognised MBL resistance genes 
109 110
. 
           In our phenotypic study, MBL E-test was found to be the most sensitive. This is in 
accordance to other studies by Behera 2008 
111
 and Yousefi 2010 
107
. 
              Study by Behera 2008 
111
 showed that both combined disc test and E test are 
equally sensitive for MBL detection and combined disc test is easy and economical. But 
in our study combined disc showed least sensitivity compared to other tests. 
       Genotypic detection of blaVIM gene and blaIMP gene were done for ten isolates (7 were 
A. baumannii, and 3 were P.aeruginosa) 
            In our study, among 3 Pseudomonas aeruginosa isolates, all were positive for 
blaIMP gene. None of the isolates was positive for blaVIM gene.  
  This is similar to the study by Fallah 
112
 in 2013 where  6 P.aeruginosa isolates were 
positive for bla (IMP) gene, while bla(VIM) gene was not detected in any isolate.  
       But a study by Aghamiri in 2014
113
 indicated that 20 (9%) of P.aeruginosa strains 
contained the IMP gene, whereas 70 (33%) of them harbored the VIM gene and a study 
by Hirataka 2003 
13 
showed that blaIMP positive Pseudomonas aeruginosa isolates were 
more frequently resistant to multiple drugs and cause more serious infections. 
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             Among 7 Acinetobacter baumannii isolates, four were positive for blaIMP gene 
and three for blaVIM gene and one  was positive for both blaVIM gene and blaIMP gene.  
           A study by Karthika 2009 
15
 in Puducherry showed 42% of Acinetobacter 
baumannii isolates showed blaIMP gene where none of the isolates showed blaVIM gene. 
        The increase in the frequency of MBLs presents an emerging threat of complete 
resistance to the useful drugs against these isolates in India. Hence reserved and careful 
use of antibiotics, as well as strict hygiene practices, are critical for preventing the  
emergence of complete resistance and spread of this multi drug resistant organisms in this 
country 
6.10. Environmental isolates: 
           Among sixty environmental samples, P.aeruginosa was isolated from 5 sites 
including SICU tap water, sink, Post operative ward door handle, sink, burns ward door 
handle and Acinetobater baumannii was isolated from two sites which included ICU bed 
rails and RICU sink.     
           But a study conducted by Fazeli H et al,.in 2012 
114 
showed that 45 P.aeruginosa 
isolates were obtained from hospital means such as shower, tap water, patients room and 
hospital personnel.  
      Studies by Trautmann et al 2011, Bert et al 1998, Buttery et al 1998 
115 116 117
showed 
that  P.aeruginosa was isolated from hospital tap water.  
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   Studies by Pina et al 1998 
118
 showed that A.baumanii was isolated from hospital 
environment.  
        In our study all the environmental isolates were sensitive strains. So there is no 
correlation between the hospital environmental samples and the drug resistant strains 
isolated from the clinical samples.  
     But a study conducted in Iran in 2012 
114
 showed that there is similarity between the 
environmental and hospital strains of P.aeruginosa in phenotypic characters, antibiotic 
resistance pattern, PCR ribotyping pattern hence the hospital environment could be a 
main reservoir for P. aeruginosa infections. 
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SUMMARY 
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                                                       7.0.  SUMMARY 
        This study entitled “IDENTIFICATION OF NON FERMENTING GRAM 
NEGATIVE BACILLI FROM CLNICAL, ENVIRONMENTAL SAMPLES AND 
THEIR ANTIMICROBIAL RESISTANCE AND DETECTION OF blaVIM/blaIMP GENE 
IN IMIPENEM RESISTANT ISOLATES” was carried out in the department of 
Microbiology, Chennai Medical  College hospital and research centre, Trichy from 
August 2014 to May 2015. 
 172 isolates of NFGNB were obtained from the various clinical samples. 90 
(52.3%) isolates were from pus, followed by 36 (20.9) from sputum, 17 
(9.8%) from urine, 11 (6.3%) from ear swab, 9 (5.2%) from ET tip, 8 (4.7%) 
from blood, 1 (0.5%) from drain tip. 
 P.aeruginosa and A .baumanii are the two common NFGNB isolated from 
the clinical specimens followed by A.lwoffii and P.fluorescens. 
 The most effective drug in this study was found to be imipenem which 
showed sensitivity percentage of 79.1% 
 The imipenem resistant isolates were detected for MBL resistance by using 
different phenotypic methods like combined disc test, Disc synergy test and 
MIC E-strip. 
 Genotypic detecetion of blaVIM gene and blaIMP gene was done using 
multiplex PCR for 10 phenotypically confirmed isolates where blaIMP was 
detected in 7 isolates (3-P.aeruginosa; 4-A.baumannii) and blaVIM was 
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detected in 3 isolates (3-A.baumannii) and both the genes were detected in 
one isolate of A.baumanii. 
 Among sixty environmental samples, P.aeruginosa was isolated in 5 sites 
including SICU tap water, sink, post operative ward door handle, sink, burns 
ward door handle and Acinetobater baumannii was isolates from two sites 
including ICU bed rails and RICU sink. 
 All strains isolated were sensitive strains.  
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                                           CONCLUSION 
             NFGNB are emerging as important opportunistic pathogens and are resistant to 
commonly used antibiotics.  
            The present study highlights the importance of speciating NFGNB and to know 
the resistance of carbapenems in these isolates. 
Prevalance of pathogens often varies between hospitals, among different patients in the 
same hospital. So it is important for clinicians to remain updated with prevalance and 
antimicrobial susceptibility pattern of the circulating pathogens and the antibiotics to be 
used for empiric therapy should be selected accordingly.  
            More importantly these organisms have great potential to survive in hospital 
environment, so effective methods of sterilization and infection control measures like 
hand hygiene, using personal protective equipments, environmental cleaning and 
disinfection, sterilization and disinfection of various instruments and devices used in 
patient care and biomedical waste management should be implemented. 
        Continuous awareness of the need to maintain good housekeeping, equipment 
decontamination, strict attention to hand washing and isolation procedures and control of 
antibiotic usage especially in high risk areas should be implemented. 
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STRENGTH: 
       1. Genotyping was carried out apart from phenotypic methods. 
       2. Not only clinical samples but also environmental samples were processed.     
LIMITS: 
1. It is a single center study 
2. Detection of MBL genes was done only for 10 imipinem resistant isolates. 
3. Other antibiotic resistance mechanisms like ESBL detection, ampC detection were 
not performed 
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MASTER CHART 
S 
NO 
ID NO SE
X 
AG
E 
SAMP
LE 
ISOLATE WARD O
P
/I
P 
C
I
P 
L
E
V 
A
K 
G C
A
Z 
CP
M 
P
I
T 
A
T 
I
M
I 
M
E
R 
R
E
S 
1 110624
6 
F 26 ear 
swab 
P.aeruginosa ENT O
P 
S S S S S S S S S S I 
2 157438 F 12 Pus P.aeruginosa paediatric I
P 
S S S R S S S S S S I 
3 153410 F 65 Pus A.baumannii ortho I
P 
R S S S R R R R R S I 
4 157716 F 57 Pus A.lwoffii surgery I
P 
S S R S S S S S S S I 
5 111000
8 
M 63 Pus P.aeruginosa ENT O
P 
R S S R R R S S S S I 
6 156974 F 38 Pus P.aeruginosa ortho I
P 
R R S R R R R S S S I 
7 153694 M 59 Pus P.aeruginosa ortho I
P 
R R S S R S S S S S I 
8 158342 F 33 Pus A.baumannii burns I
P 
R R S R R R R S S S I 
9 154808 F 45 Pus P.aeruginosa OG I
P 
S R S S S S S S S S I 
10 159160 F 11 ear 
swab 
P.fluorescens ENT I
P 
S R S S S S R R S S I 
11 158193 M 78 Pus P.aeruginosa surgery I
P 
S S S S S S S S S S I 
12 158857 M 40 Pus A.baumannii thoracic 
medicine 
I
P 
S S S S S S S S S S I 
13 159308 M 34 ear 
swab 
P.aeruginosa ENT I
P 
S S S S S S S S S S I 
14 158141 M 57 Pus P.aeruginosa surgery I
P 
R S R R S S S R S S I 
15 158350 M 33 Pus P.aeruginosa burns I
P 
S S S S S S R R S S I 
16 157328 F 28 Pus P.aeruginosa burns I
P 
S S R R S S S S S S I 
17 111793
1 
M 32 ear 
swab 
P.fluorescens ENT O
P 
S S S S S S S S S S I 
18 160554 M 86 Pus P.fluorescens surgery I
P 
S S S S S S R S S S I 
19 160486 M 48 Pus P.aeruginosa surgery I
P 
S S S S S S S S S S I 
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20 113355
0 
M 46 Pus A.baumannii surgery O
P 
S S S S S S S S S S I 
21 160540 M 43 Pus A.baumannii burns I
P 
S S R R R R R R R S I 
22 160404 M 25 Pus P.aeruginosa surgery I
P 
R S R R R R S R S S I 
23 160965 F 45 Pus P.aeruginosa thoracic 
medicine 
I
P 
R R R R S R S S S S I 
24 161108 M 22 Pus P.fluorescens ortho I
P 
S R S S S S S S S S I 
25 160549 M 38 Pus P.aeruginosa icu I
P 
S S S S S S R R R S I 
26 161221
3 
M 11 ear 
swab 
A.lwoffii paediatric I
P 
R R S S S S R S S S I 
27 161188 M 20 Pus P.aeruginosa ortho I
P 
R R R R R S S S R R I 
28 160133 M 61 Pus P.aeruginosa surgery I
P 
S R S S S S S S S S I 
29 182659 F 32 Pus A.baumannii surgery I
P 
R R R R R R R S R R I 
30 160333 M 34 Pus P.aeruginosa ortho I
P 
S S S S R R R S R R I 
31 162012 M 34 Pus P.aeruginosa surgery I
P 
S S S S S S S S S S I 
32 162829 M 65 Pus A.baumannii medicine I
P 
R S R R R R R S R R I 
33 163227 M 6 Pus A.lwoffii paediatric I
P 
S R S S S S S R S S I 
34 163337 M 10 Pus P.aeruginosa paediatric I
P 
S R S S S S S S S S I 
35 160133 M 61 Pus P.aeruginosa surgery I
P 
S S S S S S S S S S I 
36 163668 M 42 Pus A.baumannii surgery I
P 
S S R R R R R R R R I 
37 184578 M 63 Pus A.baumannii surgery I
P 
R R R R R R R S R R I 
38 164005 M 45 Pus A.lwoffii surgery I
P 
R S R R S R R R S S I 
39 162002 M 55 Pus P.aeruginosa ortho I
P 
S S S S S S S S S S I 
40 163003 M 45 drain 
tip 
A.lwoffii OG I
P 
S S S S S S S S S S I 
41 115925
0 
F 70 ear 
swab 
A.lwoffii ENT O
P 
S S S S R S S R S S I 
42 163858 M 38 Pus P.aeruginosa medicine I
P 
S R S S S R S R S S I 
43 162591 M 56 Pus P.aeruginosa surgery I S S S S S S S S S S I 
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P 
44 165299 M 50 Pus A.lwoffii OG I
P 
S S R S S S S R S S I 
45 165370 M 64 Pus A.lwoffii surgery I
P 
S S S S S S S S S S I 
46 114528
2 
M 65 Pus P.aeruginosa surgery O
P 
R R R R R R R R R R I 
47 101835
2 
M 35 Pus A.baumannii surgery I
P 
S S S S S S S R S S I 
48 165153 M 22 Pus P.aeruginosa surgery I
P 
R R R R R R R R R R I 
49 165222 F 21 Pus P.aeruginosa ortho I
P 
S S R R S S S S S S I 
50 164578 M 70 Pus P.fluorescens ortho I
P 
R R S R R R R S R R I 
51 165216 M 20 Pus P.aeruginosa ortho I
P 
R R R R R R S S R R I 
52 166534 M 52 Pus A.baumannii  I
P 
R R S S R R R S R R I 
53 166187 F 47 Pus P.aeruginosa surgery I
P 
S R S S R S S S S S I 
54 160581 M 55 Pus A.lwoffii OG I
P 
S S S S S S S S S S I 
55 164816 F 40 Pus A.lwoffii ENT I
P 
S S S S S S S S S S I 
56 750283 F 37 Pus P.aeruginosa ortho O
P 
R R S R R R S R S S I 
57 165956 F 40 Pus P.fluorescens surgery I
P 
S S S S S S S S S S I 
58 646668 M 65 Pus P.aeruginosa OG O
P 
R S S S S S S S S S I 
59 105609
9 
F 22 ear 
swab 
P.aeruginosa ENT O
P 
S S S S S S S S S S I 
60 114915
9 
F 65 Pus A.lwoffii surgery O
P 
S S S R S S S S S S I 
61 118074
2 
M 17 ear 
swab 
P.aeruginosa ENT O
P 
S R S S S S S S S S I 
62 166850 M 35 Pus A.baumannii surgery I
P 
R R R R R R R S R R I 
63 167617 M 37 Pus P.aeruginosa surgery I
P 
S S S S S S S S S S I 
64 118324
0 
M 53 Pus P.aeruginosa surgery O
P 
S S S S S S S S S S I 
65 168125 F 60 Pus A.baumannii burns I
P 
R R R R R R R S R R I 
66 113469
3 
F 36 Pus A.lwoffii surgery O
P 
S S R R S S S S S S I 
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67 167901 M 12 Pus P.aeruginosa icu I
P 
S S S S S S S S S S I 
68 168127 F 20 Pus P.fluorescens OG I
P 
S S S S S S S S S S I 
69 112731
8 
M 34 Pus A.lwoffii ortho O
P 
S S S S R S S S S S I 
70 167335 M 33 Pus P.aeruginosa surgery I
P 
S S S S S S S S S S I 
71 168888 F 70 Pus A.baumannii surgery I
P 
R R R R R R R S R R I 
72 168909 F 32 Pus P.aeruginosa burns I
P 
R R R R R R R R R R I 
73 111570
7 
M 29 ear 
swab 
P.aeruginosa icu I
P 
S S S S S S S S S S I 
74 169042 F 45 Pus A.lwoffii icu I
P 
S S S S S S S S S S I 
75 166738 F 55 Pus P.aeruginosa ortho I
P 
R R R R R R S R S S I 
76 168927 M 69 Pus P.aeruginosa surgery I
P 
R R R R R R R R S S I 
77 166692 F 60 Pus P.fluorescens OG I
P 
S S S S S S S S S S I 
78 169314 M 35 Pus P.aeruginosa ortho I
P 
R R R R S S S S S S I 
79 169917 F 81 Pus P.fluorescens ENT I
P 
S S S S S S S S S S I 
80 169938 M 6 Pus P.aeruginosa ortho I
P 
S S S S S S S S S S I 
81 168120 F 45 sputu
m 
P.aeruginosa icu I
P 
S S S S S S S S S S I 
82 170105 F 27 Pus P.aeruginosa surgery I
P 
R R S R R S S S S S I 
83 170260 M 55 Pus Schwanella surgery I
P 
S S S S S S S S S S I 
84 120023
5 
F 75 Pus P.aeruginosa surgery I
P 
S S S S S S S S S S I 
85 169405 M 10 ear 
swab 
A.lwoffii ENT I
P 
S S S S S S S S S S I 
86 169042 F 55 Pus A.baumannii surgery I
P 
R S R R R R R S R R I 
87 170591 M 58 Pus P.aeruginosa ortho I
P 
R R R R R R R S R R I 
88 170620 M 65 Pus A.baumannii ortho I
P 
R R R R R R R S R R I 
89 169996 M 70 Pus P.aeruginosa ortho I
P 
R S R R R R R S R R I 
90 120356 M 50 Pus P.aeruginosa surgery I S R R R R R R R S S I 
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8 P 
91 17039 M 65 Pus P.fluorescens surgery I
P 
S S R R S R R R R S I 
92 170929 F 65 Pus A.baumannii OG I
P 
R R S S R R R S S S I 
93 170337 M 48 Pus P.aeruginosa ENT I
P 
R R R R R R S S S S I 
94 170926 M 47 sputu
m 
P.aeruginosa icu I
P 
S S S S S S S S S S I 
95 169456 F 18 sputu
m 
P.aeruginosa icu I
P 
S S S S S S S S S S I 
96 171036 M 83 sputu
m 
P.aeruginosa icu I
P 
S S S S R S S S S S I 
97 171215 M 50 sputu
m 
P.aeruginosa thoracic 
medicine 
O
P 
S S S S S S S S S S I 
98 170260 F 46 sputu
m 
Flavobacteriu
m 
icu I
P 
S S S S R S S S S S D 
99 156874 M 51 sputu
m 
P.aeruginosa thoracic 
medicine 
I
P 
S S S S R S S S S R I 
10
0 
160794 M 51 sputu
m 
P.aeruginosa thoracic 
medicine 
O
P 
S S S S S S S S S S I 
10
1 
162975 F 45 sputu
m 
P.aeruginosa thoracic 
medicine 
I
P 
S S S S S S S S S S I 
10
2 
115291
7 
M 47 sputu
m 
P.aeruginosa thoracic 
medicine 
O
P 
S S S S S S S S S S I 
10
3 
163722 M 45 sputu
m 
P.aeruginosa thoracic 
medicine 
I
P 
S S S S S S S S S S I 
10
4 
163899 M 68 sputu
m 
Flavobacteriu
m 
thoracic 
medicine 
I
P 
S S S S S S S S S S I 
10
5 
116333
9 
M 78 sputu
m 
A.lwoffii thoracic 
medicine 
I
P 
S S S S S S S S S S I 
10
6 
165367 M 65 sputu
m 
P.aeruginosa thoracic 
medicine 
I
P 
S S S S S S S S S S I 
10
7 
110036
5 
M 15 sputu
m 
P.aeruginosa thoracic 
medicine 
I
P 
S S S S S S S S S S I 
10
8 
166644 M 35 sputu
m 
P.aeruginosa thoracic 
medicine 
I
P 
R R S S S S S S S S I 
10
9 
165551 M 66 sputu
m 
A.baumannii thoracic 
medicine 
I
P 
S S S S S S S S S S I 
11
0 
166971 M 62 sputu
m 
Achromobact
er 
thoracic 
medicine 
I
P 
S S S S S S S S S S I 
11
1 
167378 M 65 sputu
m 
P.aeruginosa thoracic 
medicine 
I
P 
S S S S S S S S S S I 
11
21 
167481 M 55 sputu
m 
P.aeruginosa thoracic 
medicine 
I
P 
S S S S S R S R S S I 
13 167336 M 47 sputu
m 
A.baumannii thoracic 
medicine 
I
P 
S S R S R R R S R R I 
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11
4 
167619 F 29 sputu
m 
A.lwoffii thoracic 
medicine 
I
P 
S S S S S S S S S S I 
11
5 
167860 M 65 sputu
m 
A.baumannii thoracic 
medicine 
I
P 
S S S R S R R S R R I 
11
6 
168350 F 57 sputu
m 
A.baumannii thoracic 
medicine 
I
P 
R R S R R R S S R R I 
11
7 
168491 F 55 ET  tip A.baumannii icu I
P 
S R R R R R R S R S I 
11
8 
169514 M 50 sputu
m 
Achromobact
er 
thoracic 
medicine 
I
P 
S S S S S S S S S S I 
11
9 
169882 M 33 sputu
m 
P.aeruginosa thoracic 
medicine 
I
P 
S S S S S S S S S S I 
12
0 
169939 F 42 Urine P.aeruginosa surgery I
P 
S S S S S S S S S S I 
12
1 
169992 M 61 Urine P.aeruginosa surgery I
P 
R R R R R R R R R R I 
12
2 
168151 M 26 Urine A.baumannii surgery I
P 
R R S S S R R S R R I 
12
3 
171251 F 33 Urine P.aeruginosa medicine I
P 
S S S S S S S S S S I 
12
4 
171257 M 54 Urine P.aeruginosa medicine I
P 
S S S S S S S S S S I 
12
5 
159595 M 75 Urine A.lwoffii medicine I
P 
S S S S S S S S S S I 
12
6 
160133 M 52 Urine A.baumannii surgery I
P 
R R R R R R R S R R I 
12
7 
160689 F 32 Urine P.aeruginosa surgery O
P 
S S S S S S S S S S I 
12
8 
164496 M 85 Urine P.aeruginosa ortho I
P 
S S S S S S S S S R I 
12
9 
164810 F 56 Urine A.baumannii medicine I
P 
S S S S S S S S S S I 
13
0 
165550 F 56 Urine P.aeruginosa surgery I
P 
S S S S R S S S S S I 
13
1 
166901 M 65 Blood A.baumannii surgery I
P 
S S S S R R S R S S I 
13
2 
117855
7 
M 55 Blood P.aeruginosa icu I
P 
S R R R R S S R S S I 
13
3 
169400 M 22 Blood A.baumannii ortho I
P 
S S S R S S S S S S I 
13
4 
157148 F 21 Blood A.baumannii medicine I
P 
S S S S S S S S S S I 
13
5 
107870
4 
F 28 Blood A.baumannii surgery I
P 
R S S S S S S S S S I 
13
6 
625614 M 10 Blood A.baumannii paediatric I
P 
R R R S R S S S S S I 
13 150813 F 69 Blood P.aeruginosa surgery I S S S S S S S S S S I 
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7 P 
13
8 
155254 M 56 Pus P.aeruginosa surgery I
P 
S S S S S S S S S S I 
13
9 
165481 F 41 Pus P.aeruginosa ortho I
P 
S S S S S S S S S S I 
14
0 
724494 F 40 Pus P.aeruginosa surgery I
P 
S S S S S S S S S R I 
14
1 
169166
0 
F 69 ear 
swab 
P.aeruginosa ENT I
P 
R S R S S S S S S S I 
14
2 
178296 M 60 Pus P.aeruginosa surgery I
P 
S S S S R R S S S S I 
14
3 
180656 F 35 Pus P.aeruginosa surgery I
P 
S S S R S S S S S S I 
14
4 
169606 F 81 Pus P.stutzeri surgery I
P 
S S S S S S S R S S I 
14
5 
171801 M 52 Pus A.baumannii surgery I
P 
S R R S R S S S R R I 
14
6 
179443 M 5 Pus P.aeruginosa thoracic 
medicine 
I
P 
S S S S S S S S S S I 
14
7 
127371
7 
F 60 Blood A.baumannii paediatric I
P 
S S S S S S S S S S I 
14
8 
179469 F 36 Pus P.aeruginosa medicine O
P 
S S S S S S S S S S I 
14
9 
180358 M 58 sputu
m 
P.aeruginosa medicine I
P 
S S S R S S S S S S I 
15
0 
179680 M 58 sputu
m 
P.aeruginosa thoracic 
medicine 
I
P 
S S S S S S S S S S I 
15
1 
178296 M 50 ET  tip P.aeruginosa icu I
P 
R R R R R R S S R R I 
15
2 
175599 M 50 ET tip P.aeruginosa icu I
P 
S S S R S S S S S S I 
15
3 
178007 F 76 sputu
m 
P.aeruginosa surgery I
P 
S S S R S S S S S S I 
15
4 
177745 M 72 sputu
m 
A.baumannii icu I
P 
S S S S S S S S S S I 
15
5 
173403 M 65 ET tip P.aeruginosa icu I
P 
S S S S S S S S S S I 
15
6 
173454 M 75 sputu
m 
P.aeruginosa icu I
P 
S S S S S S S S S S I 
15
7 
176438 M 56 sputu
m 
P.fluorescens thoracic 
medicine 
I
P 
S S S S S S S S S S I 
15
8 
176350 M 55 ET tip P.aeruginosa icu I
P 
S S S S S S S S S S I 
15
9 
176355 M 70 ET tip P.aeruginosa icu I
P 
S S S R S S R S S S I 
16
0 
180989 M 63 sputu
m 
P.aeruginosa surgery I
P 
S S S S S S S S S S I 
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16
1 
181007 M 70 sputu
m 
P.aeruginosa thoracic 
medicine 
I
P 
R R S S R R R S S S I 
16
2 
181454 M 55 ET tip P.aeruginosa icu I
P 
S S R S S S S S S S I 
16
3 
182668 F 23 ET tip P.aeruginosa icu I
P 
S S S S S S S S S S I 
16
4 
182359 F 62 sputu
m 
P.fluorescens thoracic 
medicine 
I
P 
S S S S S S S S S S I 
16
5 
182665 F 26 sputu
m 
P.aeruginosa icu I
P 
S S S S S S S S S S I 
16
6 
183623 M 60 ET tip P.aeruginosa icu I
P 
S S S R S R S S S S I 
16
7 
176123 M 12 Urine P.aeruginosa ortho I
P 
S S S S S S S S S S I 
16
8 
178082 M 47 Urine A.baumannii surgery I
P 
S S S R R R S S R R I 
16
9 
179890 F 38 Urine P.aeruginosa OG I
P 
S S S R S S S S R R I 
17
0 
179095 M 40 Urine P.aeruginosa ortho I
P 
R R R R R R R R R R I 
17
1 
180778 F 82 Urine P.aeruginosa medicine I
P 
S S S S S S S S S S I 
17
2 
178880 M 54 Urine A.baumannii surgery I
P 
S S S S S S S S S S I 
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PROFORMA 
 
 CLINICAL DETAILS 
NAME:                                                                                                                             
 
Sl.No. :  
                                                                                                                                         
            Ip . \ Op. no.  
AGE \ SEX:     
           D.O.A:  
ADDRESS:  
D.O.D:  
OCCUPATION:  
 
PRESENTING COMPLAINTS (WITH ANTIBIOTIC HISTORY):  
 
PAST HISTORY:  
Hospitalisation  
 
Treatment  
 
Any invasive procedure  
 
   
  
HISTORY OF ASSOCIATED ILLNESS: Diabetes/HIV/other immunocompromised 
status  
 
GENERAL PHYSICAL EXAMINATION:  
 
PROVISIONAL DIAGNOSIS:  
 
TREATMENT  
 
INVESTIGATIONS DONE:  
A) GENERAL:  
 
B) MICROBIOLOGY 
             Sample and date of collection:   
              Site and clinical diagnosis: 
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Culture :                                                                                  Gram Stain  
 
NA  
  
                                                          MAC --- NLF colonies – TSI -  
                BAP 
GRAMS 
 
OF 10 % LAC Decarboxylation 
PIGMENT 
 
G Es -  Lys 
OXIDASE 
 
L  Arg 
MOTILITY 
 
S  Orn  
INDOLE 
 
MAL   
UREASE 
 
MANN   
NR TEST 
 
XYLs   
 
Organism isolated -   
ANTIBIOGRAM : 
 Antibiotic  Zone  Interpretation Antibiotic Zone  interpretation 
CAZ   IMP   
CPM   MER   
AT   DOR   
PTZ      
G   COL   
AK   POL B   
CIP      
LEV   CTX   
NOR   CTR   
   DOX   
   COT   
      
 
Patient‟s response to treatment :  
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ANNEXURE II 
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